Colitis: Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.Colitis, Ulcerative: Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.Colitis, Ischemic: Inflammation of the COLON due to colonic ISCHEMIA resulting from alterations in systemic circulation or local vasculature.Colitis, Microscopic: A condition characterized by chronic watery DIARRHEA of unknown origin, a normal COLONOSCOPY but abnormal histopathology on BIOPSY. This syndrome was first described in 1980 by Read and associates. Subtypes include COLLAGENOUS COLITIS and LYMPHOCYTIC COLITIS. Both have similar clinical symptoms and are distinguishable only by histology.Dextran Sulfate: Long-chain polymer of glucose containing 17-20% sulfur. It has been used as an anticoagulant and also has been shown to inhibit the binding of HIV-1 to CD4-POSITIVE T-LYMPHOCYTES. It is commonly used as both an experimental and clinical laboratory reagent and has been investigated for use as an antiviral agent, in the treatment of hypolipidemia, and for the prevention of free radical damage, among other applications.Colitis, Collagenous: A subtype of MICROSCOPIC COLITIS, characterized by chronic watery DIARRHEA of unknown origin, a normal COLONOSCOPY but abnormal histopathology on BIOPSY. Microscopic examination of biopsy samples taken from the COLON show larger-than-normal band of subepithelial COLLAGEN.Colon: The segment of LARGE INTESTINE between the CECUM and the RECTUM. It includes the ASCENDING COLON; the TRANSVERSE COLON; the DESCENDING COLON; and the SIGMOID COLON.Trinitrobenzenesulfonic Acid: A reagent that is used to neutralize peptide terminal amino groups.Colitis, Lymphocytic: A subtype of MICROSCOPIC COLITIS, characterized by chronic watery DIARRHEA of unknown origin, a normal COLONOSCOPY but abnormal histopathology on BIOPSY. Microscopic examination of biopsy samples taken from the COLON show infiltration of LYMPHOCYTES in the superficial EPITHELIUM and the underlying connective tissue (lamina propria).Crohn Disease: A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.Intestinal Mucosa: Lining of the INTESTINES, consisting of an inner EPITHELIUM, a middle LAMINA PROPRIA, and an outer MUSCULARIS MUCOSAE. In the SMALL INTESTINE, the mucosa is characterized by a series of folds and abundance of absorptive cells (ENTEROCYTES) with MICROVILLI.Inflammatory Bowel Diseases: Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS.Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)Rectum: The distal segment of the LARGE INTESTINE, between the SIGMOID COLON and the ANAL CANAL.Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)Peroxidase: A hemeprotein from leukocytes. Deficiency of this enzyme leads to a hereditary disorder coupled with disseminated moniliasis. It catalyzes the conversion of a donor and peroxide to an oxidized donor and water. EC 1.11.1.7.Gastrointestinal Agents: Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion.Colectomy: Excision of a portion of the colon or of the whole colon. (Dorland, 28th ed)Proctocolectomy, Restorative: A surgical procedure involving the excision of the COLON and RECTUM and the formation of an ILEOANAL RESERVOIR (pouch). In patients with intestinal diseases, such as ulcerative colitis, this procedure avoids the need for an OSTOMY by allowing for transanal defecation.Disease Models, Animal: Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.Colonoscopy: Endoscopic examination, therapy or surgery of the luminal surface of the colon.Dysentery, Amebic: DYSENTERY caused by intestinal amebic infection, chiefly with ENTAMOEBA HISTOLYTICA. This condition may be associated with amebic infection of the LIVER and other distant sites.Ileostomy: Surgical creation of an external opening into the ILEUM for fecal diversion or drainage. This replacement for the RECTUM is usually created in patients with severe INFLAMMATORY BOWEL DISEASES. Loop (continent) or tube (incontinent) procedures are most often employed.Administration, Rectal: The insertion of drugs into the rectum, usually for confused or incompetent patients, like children, infants, and the very old or comatose.Enterocolitis, Pseudomembranous: An acute inflammation of the INTESTINAL MUCOSA that is characterized by the presence of pseudomembranes or plaques in the SMALL INTESTINE (pseudomembranous enteritis) and the LARGE INTESTINE (pseudomembranous colitis). It is commonly associated with antibiotic therapy and CLOSTRIDIUM DIFFICILE colonization.Pouchitis: Acute INFLAMMATION in the INTESTINAL MUCOSA of the continent ileal reservoir (or pouch) in patients who have undergone ILEOSTOMY and restorative proctocolectomy (PROCTOCOLECTOMY, RESTORATIVE).Mice, Inbred C57BLEnterocolitis: Inflammation of the MUCOSA of both the SMALL INTESTINE and the LARGE INTESTINE. Etiology includes ISCHEMIA, infections, allergic, and immune responses.Mice, Knockout: Strains of mice in which certain GENES of their GENOMES have been disrupted, or "knocked-out". To produce knockouts, using RECOMBINANT DNA technology, the normal DNA sequence of the gene being studied is altered to prevent synthesis of a normal gene product. Cloned cells in which this DNA alteration is successful are then injected into mouse EMBRYOS to produce chimeric mice. The chimeric mice are then bred to yield a strain in which all the cells of the mouse contain the disrupted gene. Knockout mice are used as EXPERIMENTAL ANIMAL MODELS for diseases (DISEASE MODELS, ANIMAL) and to clarify the functions of the genes.Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.Colonic Pouches: Sacs or reservoirs created to function in place of the COLON and/or RECTUM in patients who have undergone restorative proctocolectomy (PROCTOCOLECTOMY, RESTORATIVE).Acetic Acid: Product of the oxidation of ethanol and of the destructive distillation of wood. It is used locally, occasionally internally, as a counterirritant and also as a reagent. (Stedman, 26th ed)Intestines: The section of the alimentary canal from the STOMACH to the ANAL CANAL. It includes the LARGE INTESTINE and SMALL INTESTINE.Probiotics: Live microbial DIETARY SUPPLEMENTS which beneficially affect the host animal by improving its intestinal microbial balance. Antibiotics and other related compounds are not included in this definition. In humans, lactobacilli are commonly used as probiotics, either as single species or in mixed culture with other bacteria. Other genera that have been used are bifidobacteria and streptococci. (J. Nutr. 1995;125:1401-12)Interleukin-10: A cytokine produced by a variety of cell types, including T-LYMPHOCYTES; MONOCYTES; DENDRITIC CELLS; and EPITHELIAL CELLS that exerts a variety of effects on immunoregulation and INFLAMMATION. Interleukin-10 combines with itself to form a homodimeric molecule that is the biologically active form of the protein.Cytokines: Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner.Cecum: The blind sac or outpouching area of the LARGE INTESTINE that is below the entrance of the SMALL INTESTINE. It has a worm-like extension, the vermiform APPENDIX.Citrobacter rodentium: A species of gram-negative bacteria in the genus CITROBACTER, family ENTEROBACTERIACEAE. As an important pathogen of laboratory mice, it serves as a model for investigating epithelial hyperproliferation and tumor promotion. It was previously considered a strain of CITROBACTER FREUNDII.Ileitis: Inflammation of any segment of the ILEUM and the ILEOCECAL VALVE.Feces: Excrement from the INTESTINES, containing unabsorbed solids, waste products, secretions, and BACTERIA of the DIGESTIVE SYSTEM.Helicobacter hepaticus: A species of HELICOBACTER that colonizes the CECUM and COLON of several strains of MICE, and is associated with HEPATITIS and carcinogenesis.Mice, Inbred BALB CAnti-Inflammatory Agents, Non-Steroidal: Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions.They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.Megacolon, Toxic: An acute form of MEGACOLON, severe pathological dilatation of the COLON. It is associated with clinical conditions such as ULCERATIVE COLITIS; CROHN DISEASE; AMEBIC DYSENTERY; or CLOSTRIDIUM ENTEROCOLITIS.Ileum: The distal and narrowest portion of the SMALL INTESTINE, between the JEJUNUM and the ILEOCECAL VALVE of the LARGE INTESTINE.Oxazolone: Immunologic adjuvant and sensitizing agent.Biopsy: Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.Clostridium difficile: A common inhabitant of the colon flora in human infants and sometimes in adults. It produces a toxin that causes pseudomembranous enterocolitis (ENTEROCOLITIS, PSEUDOMEMBRANOUS) in patients receiving antibiotic therapy.Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.Colon, Sigmoid: A segment of the COLON between the RECTUM and the descending colon.Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care. (Dictionary of Health Services Management, 2d ed)Sigmoidoscopy: Endoscopic examination, therapy or surgery of the sigmoid flexure.Colonic Diseases: Pathological processes in the COLON region of the large intestine (INTESTINE, LARGE).Proctitis: INFLAMMATION of the MUCOUS MEMBRANE of the RECTUM, the distal end of the large intestine (INTESTINE, LARGE).Intestine, Large: A segment of the LOWER GASTROINTESTINAL TRACT that includes the CECUM; the COLON; and the RECTUM.Cholangitis, Sclerosing: Chronic inflammatory disease of the BILIARY TRACT. It is characterized by fibrosis and hardening of the intrahepatic and extrahepatic biliary ductal systems leading to bile duct strictures, CHOLESTASIS, and eventual BILIARY CIRRHOSIS.Mucous Membrane: An EPITHELIUM with MUCUS-secreting cells, such as GOBLET CELLS. It forms the lining of many body cavities, such as the DIGESTIVE TRACT, the RESPIRATORY TRACT, and the reproductive tract. Mucosa, rich in blood and lymph vessels, comprises an inner epithelium, a middle layer (lamina propria) of loose CONNECTIVE TISSUE, and an outer layer (muscularis mucosae) of SMOOTH MUSCLE CELLS that separates the mucosa from submucosa.Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)Colonic Neoplasms: Tumors or cancer of the COLON.Proctocolitis: Inflammation of the RECTUM and the distal portion of the COLON.Acute Disease: Disease having a short and relatively severe course.Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.Tumor Necrosis Factor-alpha: Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS.Dinitrofluorobenzene: Irritants and reagents for labeling terminal amino acid groups.Gastrointestinal Hemorrhage: Bleeding in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM.Bacterial Translocation: The passage of viable bacteria from the GASTROINTESTINAL TRACT to extra-intestinal sites, such as the mesenteric lymph node complex, liver, spleen, kidney, and blood. Factors that promote bacterial translocation include overgrowth with gram-negative enteric bacilli, impaired host immune defenses, and injury to the INTESTINAL MUCOSA resulting in increased intestinal permeability. Bacterial translocation from the lung to the circulation is also possible and sometimes accompanies MECHANICAL VENTILATION.Mesentery: A layer of the peritoneum which attaches the abdominal viscera to the ABDOMINAL WALL and conveys their blood vessels and nerves.Clostridium Infections: Infections with bacteria of the genus CLOSTRIDIUM.Collagen Diseases: Historically, a heterogeneous group of acute and chronic diseases, including rheumatoid arthritis, systemic lupus erythematosus, progressive systemic sclerosis, dermatomyositis, etc. This classification was based on the notion that "collagen" was equivalent to "connective tissue", but with the present recognition of the different types of collagen and the aggregates derived from them as distinct entities, the term "collagen diseases" now pertains exclusively to those inherited conditions in which the primary defect is at the gene level and affects collagen biosynthesis, post-translational modification, or extracellular processing directly. (From Cecil Textbook of Medicine, 19th ed, p1494)CD4-Positive T-Lymphocytes: A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes.Severity of Illness Index: Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder.Ulcer: A lesion on the surface of the skin or a mucous surface, produced by the sloughing of inflammatory necrotic tissue.Mucin-2: A gel-forming mucin found predominantly in SMALL INTESTINE and variety of mucous membrane-containing organs. It provides a protective, lubricating barrier against particles and infectious agents.Administration, Oral: The giving of drugs, chemicals, or other substances by mouth.

Histocompatibility antigens in inflammatory bowel disease. Their clinical significance and their association with arthropathy with special reference to HLA-B27 (W27). (1/3046)

Histocompatibility (HLA) antigen phenotypes have been studied in 100 patients with ulcerative colitis, 100 with Crohn's disease, and 283 normal controls. In addition the incidence of ankylosing spondylitis, sacroiliitis, and "enteropathic" peripheral arthropathy was determined in the patients with inflammatory bowel disease (IBD). There was no significant difference in antigen frequency between patients and controls. However, the incidence of HLA-B27 was increased in the patients complicated by ankylosing spondylitis and/or sacroiliitis in both ulcerative colitis and Crohn's disease. In contrast, none of the 29 IBD patients with "enteropathic" peripheral arthropathy had B27 antigen. Furthermore, ankylosing spondylitis was found more frequently in ulcerative colitis bearing HLA-B27 compared with non-B27 patients (P less than 0-01). The same was found in Crohn's disease, although this difference was not statistically significant. In addition, 12 of 14 ulcerative colitis patients and five out of six Crohn's patients with HLA-B27 had total colitis, compared with the frequency of total colitis in non-B27 patients (P less than 0-024 and less than 0-03 respectively). The data suggest that B27 histocompatibility antigen could be a pathogenetic discriminator between the arthropathies in IBD and may be of prognostic significance with respect to extension and severity of the disease.  (+info)

Expression of nitric oxide synthase in inflammatory bowel disease is not affected by corticosteroid treatment. (2/3046)

AIM: To examine the effect of corticosteroid treatment on the expression of inducible nitric oxide synthase (iNOS) in the colon of patients with inflammatory bowel disease. METHODS: Four groups of patients were studied: (1) ulcerative colitis treated with high dose corticosteroids (six patients, 10 blocks); (2) ulcerative colitis patients who had never received corticosteroids (10 patients, 16 blocks); (3) Crohn's disease treated with high dose corticosteroids (12 patients, 24 blocks); (4) Non-inflammatory, non-neoplastic controls (four patients, six blocks). Full thickness paraffin sections of colons removed at surgery were immunostained with an antibody raised against the C terminal end of iNOS. Sections were assessed semiquantitatively for the presence and degree of inflammation and immunoreactivity for nitric oxide synthase. RESULTS: Cases of ulcerative colitis and Crohn's disease with active inflammation showed strong staining for nitric oxide synthase. The staining was diffuse in ulcerative colitis and patchy in Crohn's disease, in accordance with the distribution of active inflammation. Staining was seen in epithelial cells and was most intense near areas of inflammation such as crypt abscesses. Non-inflamed epithelium showed no immunoreactivity. Treatment with corticosteroids made no difference to the amount of nitric oxide synthase. CONCLUSIONS: Expression of nitric oxide synthase is increased in both ulcerative colitis and Crohn's disease and appears to be unaffected by treatment with corticosteroids. Disease severity necessitated surgery in all the cases included in this study, regardless of whether or not the patients had received long term corticosteroid treatment. It seems therefore that a high level of iNOS expression and, presumably, production of nitric oxide characterise cases which are refractory to clinical treatment; this suggests that specific inhibition of the enzyme may be a useful therapeutic adjunct.  (+info)

Perioperative growth hormone treatment and functional outcome after major abdominal surgery: a randomized, double-blind, controlled study. (3/3046)

OBJECTIVE: To evaluate short- and long-term effects of perioperative human growth hormone (hGH) treatment on physical performance and fatigue in younger patients undergoing a major abdominal operation in a normal postoperative regimen with oral nutrition. SUMMARY BACKGROUND DATA: Muscle wasting and functional impairment follow major abdominal surgery. METHODS: Twenty-four patients with ulcerative colitis undergoing ileoanal J-pouch surgery were randomized to hGH (12 IU/day) or placebo treatment from 2 days before to 7 days after surgery. Measurements were performed 2 days before and 10, 30, and 90 days after surgery. RESULTS: The total muscle strength of four limb muscle groups was reduced by 7.6% in the hGH group and by 17.1% in the placebo group at postoperative day 10 compared with baseline values. There was also a significant difference between treatment groups in total muscle strength at day 30, and at the 90-day follow-up total muscle strength was equal to baseline values in the hGH group, but still significantly 5.9% below in the placebo group. The work capacity decreased by approximately 20% at day 10 after surgery, with no significant difference between treatment groups. Both groups were equally fatigued at day 10 after surgery, but at day 30 and 90 the hGH patients were less fatigued than the placebo patients. During the treatment period, patients receiving hGH had reduced loss of limb lean tissue mass, and 3 months after surgery the hGH patients had regained more lean tissue mass than placebo patients. CONCLUSIONS: Perioperative hGH treatment of younger patients undergoing major abdominal surgery preserved limb lean tissue mass, increased postoperative muscular strength, and reduced long-term postoperative fatigue.  (+info)

Biased JH usage in plasma cell immunoglobulin gene sequences from colonic mucosa in ulcerative colitis but not in Crohn's disease. (4/3046)

BACKGROUND: Ulcerative colitis is an inflammatory disease of the colonic and rectal mucosa. Autoantibodies have been observed in ulcerative colitis which may have a role in the pathogenesis of the disease. Evidence also suggests that there is an hereditary predisposition towards the disease, although no individual genes have been identified. AIMS: This is a pilot study of immunoglobulin heavy chain genes (IgH) in ulcerative colitis to determine whether they have any particular genetic characteristics which may lead to a better understanding of the disease aetiology. SUBJECTS: Colonic or rectal tissue was obtained from five children with ulcerative colitis. Tissue was also obtained from five children with Crohn's disease and five children who did not have inflammatory bowel disease as controls. METHODS: B cells and IgD+ B cells were identified by immunohistochemistry on frozen sections. Areas of lamina propria containing plasma cells, and areas of IgD+ B cells were microdissected. The immunoglobulin genes were PCR amplified, cloned, and sequenced. Sequences were analysed for content of somatic mutations and composition of heavy chain. RESULTS: An increase in the use of JH6 and DXP'1, and a decrease in the use of JH4, gene segments in immunoglobulin genes from lamina propria plasma cells, and from virgin IgD+ B cells, was found in patients with ulcerative colitis. These biases were not present in the control groups. CONCLUSIONS: There is a fundamental difference in the immunoglobulin genes from patients with ulcerative colitis. Whether this is caused by a difference in content of immunoglobulin gene segments in the germline or a difference in the recombination mechanism is not known.  (+info)

Sulphation and secretion of the predominant secretory human colonic mucin MUC2 in ulcerative colitis. (5/3046)

BACKGROUND: Decreased synthesis of the predominant secretory human colonic mucin (MUC2) occurs during active ulcerative colitis. AIMS: To study possible alterations in mucin sulphation and mucin secretion, which could be the cause of decreased mucosal protection in ulcerative colitis. METHODS: Colonic biopsy specimens from patients with active ulcerative colitis, ulcerative colitis in remission, and controls were metabolically labelled with [35S]-amino acids or [35S]-sulphate, chase incubated and analysed by SDS-PAGE, followed by quantitation of mature [35S]-labelled MUC2. For quantitation of total MUC2, which includes non-radiolabelled and radiolabelled MUC2, dot blotting was performed, using a MUC2 monoclonal antibody. RESULTS: Between patient groups, no significant differences were found in [35S]-sulphate content of secreted MUC2 or in the secreted percentage of either [35S]-amino acid labelled MUC2 or total MUC2. During active ulcerative colitis, secretion of [35S]-sulphate labelled MUC2 was significantly increased twofold, whereas [35S]-sulphate incorporation into MUC2 was significantly reduced to half. CONCLUSIONS: During active ulcerative colitis, less MUC2 is secreted, because MUC2 synthesis is decreased while the secreted percentage of MUC2 is unaltered. Furthermore, sulphate content of secreted MUC2 is unaltered by a specific compensatory mechanism, because sulphated MUC2 is preferentially secreted while sulphate incorporation into MUC2 is reduced.  (+info)

A genomewide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort. (6/3046)

Inflammatory bowel disease (IBD) is characterized by a chronic relapsing intestinal inflammation, typically starting in early adulthood. IBD is subdivided into two subtypes, on the basis of clinical and histologic features: Crohn disease and ulcerative colitis (UC). Previous genomewide searches identified regions harboring susceptibility loci on chromosomes 1, 3, 4, 7, 12, and 16. To expand our understanding of the genetic risk profile, we performed a 9-cM genomewide search for susceptibility loci in 268 families containing 353 affected sibling pairs. Previous linkages on chromosomes 12 and 16 were replicated, and the chromosome 4 linkage was extended in this sample. New suggestive evidence for autosomal linkages was observed on chromosomes 1, 6, 10, and 22, with LOD scores of 2.08, 2.07, 2.30, and 1.52, respectively. A maximum LOD score of 1.76 was observed on the X chromosome, for UC, which is consistent with the clinical association of IBD with Ullrich-Turner syndrome. The linkage finding on chromosome 6p is of interest, given the possible contribution of human leukocyte antigen and tumor necrosis-factor genes in IBD. This genomewide linkage scan, done with a large family cohort, has confirmed three previous IBD linkages and has provided evidence for five additional regions that may harbor IBD predisposition genes.  (+info)

The systemic load and efficient delivery of active 5-aminosalicylic acid in patients with ulcerative colitis on treatment with olsalazine or mesalazine. (7/3046)

BACKGROUND: There have been reports of nephrotoxic reactions in patients with ulcerative colitis treated with 5-aminosalicylic acid (5-ASA) preparations. AIM: To compare the efficacy in delivery of active 5-ASA to the colon and the systemic load as the basis for potential long-term toxicity during treatment with olsalazine or mesalazine in patients with ulcerative colitis in remission. PATIENTS AND METHODS: Fifteen patients with ulcerative colitis were treated with olsalazine or mesalazine, each for 7 days in an open, randomized, crossover design study. 5-ASA and acetyl-5-ASA (Ac-5-ASA) in plasma and urine were measured by high performance liquid chromatography. RESULTS: The plasma concentration of 5-ASA was 1.2 +/- 0.1 micromol/L (mean +/- S.E.M.) for olsalazine and 8.0 +/- 1.9 micromol/L for mesalazine, while the plasma concentration of Ac-5-ASA was 2.8 +/- 0.2 micromol/L for olsalazine and 10.8 +/- 1.6 micromol/L for mesalazine. The amount of 5-ASA excreted in the urine was 68 +/- 30 micromol/24 h for olsalazine and 593 +/- 164 micromol/24 h for mesalazine. The amount of Ac-5-ASA in the urine was 1260 +/- 102 micromol/24 h for olsalazine and 3223 +/- 229 micromol/24 h for mesalazine. The urinary recovery of total 5-ASA plus Ac-5-ASA (as a percentage of the given dose) was 23 +/- 2.1% for olsalazine and 39 +/- 3.6% for mesalazine. The ratio between the plasma concentrations of mesalazine and olsalazine differed significantly both for 5-ASA (5.1) and Ac-5-ASA (3.6); for 5-ASA (9. 9) and Ac-5-ASA (2.6) in urine, and for the urinary recovery of total 5-ASA plus Ac-5-ASA (1.7). Moreover, in the mesalazine group there was a large variation in the individual plasma concentrations of 5-ASA and Ac-5-ASA, with maximal values 5-6-fold higher than that in the olsalazine group. CONCLUSION: The systemic load of active 5-ASA is significantly higher for mesalazine than for olsalazine, when based on the dosages given and when calculated on an equimolar basis. Some of the patients in the mesalazine group showed unexpected high levels of plasma and urinary 5-ASA concentrations, a finding which may have long-term safety implications.  (+info)

Is maintenance therapy always necessary for patients with ulcerative colitis in remission? (8/3046)

BACKGROUND: The efficacy of sulphasalazine and mesalazine in preventing relapse in patients with ulcerative colitis is well known. It is less clear how long such maintenance should be continued, and if the duration of disease remission is a factor that affects the risk of recurrence. AIM: To determine whether the duration of disease remission affects the relapse rate, by comparing the efficacy of a delayed-release mesalazine (Asacol, Bracco S.p.A., Milan, Italy) against placebo in patients with ulcerative colitis with short- and long-duration of disease remission. METHODS: 112 patients (66 male, 46 female, mean age 35 years), with intermittent chronic ulcerative colitis in clinical, endoscopic and histological remission with sulphasalazine or mesalazine for at least 1 year, were included in the study. Assuming that a lower duration of remission might be associated with a higher relapse rate, the patients were stratified according to the length of their disease remission, prior to randomization into Group A (Asacol 26, placebo 35) in remission from 1 to 2 years, or Group B (Asacol 28, placebo 23) in remission for over 2 years, median 4 years. Patients were treated daily with oral Asacol 1.2 g vs. placebo, for a follow-up period of 1 year. RESULTS: We employed an intention-to-treat analysis. In Group A, whilst no difference was found between the two treatments after 6 months, mesalazine was significantly more effective than placebo in preventing relapse at 12 months [Asacol 6/26 (23%), placebo 17/35 (49%), P = 0.035, 95% Cl: 48-2.3%]. In contrast, in Group B no statistically significant difference was observed between the two treatments, either at 6 or 12 months [Asacol 5/28 (18%), placebo 6/23 (26%), P = 0.35, 95% Cl: 31-14%] of follow-up. Patients in group B were older, and had the disease and remission duration for longer, than those in Group A. CONCLUSIONS: Mesalazine prophylaxis is necessary for the prevention of relapse by patients with ulcerative colitis in remission for less than 2 years, but this study casts doubt over whether continuous maintenance treatment is necessary in patients with prolonged clinical, endoscopic and histological remission, who are at very low risk of relapse.  (+info)

*Ulcerative colitis

... at Curlie (based on DMOZ) MedlinePlus ulcerative colitis page Ulcerative colitis information page at Crohn's ... A diagnosis of ulcerative colitis may not occur until the onset of intestinal manifestations, however. Ulcerative colitis is ... One study of isotretinoin found a small increase in the rate of ulcerative colitis. Ulcerative colitis is an autoimmune disease ... The effect of curcumin therapy alone on quiescent ulcerative colitis is unknown. Patients with ulcerative colitis usually have ...

*Management of ulcerative colitis

... by the type of ulcerative colitis. Aminosalicylates are the main anti-inflammatory drugs used to treat ulcerative colitis. ... Ulcerative colitis is a form of colitis, a disease of the intestine, specifically the large intestine or colon, that includes ... Ulcerative colitis is a disease that affects many parts of the body outside the intestinal tract. In rare cases the extra- ... Ulcerative Colitis Practice Guidelines in Adults, Am. Coll. Gastroenterology, 2004. PDF Jowett, S L; Seal, C J; Pearce, M S; ...

*Anti-Saccharomyces cerevisiae antibody

In Crohn's disease and ulcerative colitis the presence of intestinal S. cerevisiae is rare, but the association with irritiable ... Celiac disease ColitisUlcerative colitis-familial. Microscopic colitis Collagenous colitis Crohn's disease Intestinal yeast and ... ASCA tends to recognize Crohn's disease more frequently, whereas pANCA tend to recognize ulcerative colitis. ASCA antibodies ... 2001). "Familial expression of anti-Saccharomyces cerevisiae Mannan antibodies in Crohn's disease and ulcerative colitis: a ...

*Pancolitis

... or universal colitis is a very severe form of ulcerative colitis. This form of ulcerative colitis is spread ... "Ulcerative Colitis Symptoms, Diet, Treatment & Medication". Retrieved 2016-06-27. "Ulcerative colitis". 2016-03-17. Retrieved ... Surgery for ulcerative colitis. Surgeon (Edinburgh University Press), 5(6), 356-362. Description of UC Pan Colitis Patients UC ... Patients with ulcerative colitis generally exhibit symptoms including rectal bleeding as a result of ulcers, pain in the ...

*Aminosalicylate

An aminosalicylate is a class of medications that is often used to treat ulcerative colitis and Crohn's disease. The class ...

*Human digestive system

Ulcerative colitis an ulcerative form of colitis, is the other major inflammatory bowel disease which is restricted to the ... Danese, S. & Fiocci, C. (2011). Ulcerative colitis. The New England Journal of Medicine, 365:1713-1725. Thompson WG, Longstreth ... Ulcerative coliltis is the most common of the IBDs Irritable bowel syndrome (IBS) is the most common of the functional ...

*Blood in stool

... or in the colon if a person has ulcerative colitis. Crohns disease Ulcerative colitis Enteritis-inflammation of the small ... "Ulcerative Colitis". NIDDK. September 2014. Retrieved Dec 6, 2017. "Crohn's disease: Symptoms". MayoClinic.com. 2011-08-09. ... Inflammatory bowel disease is also divided into separate conditions, namely ulcerative colitis and Crohn's disease, which have ... Colitis can be divided into infectious and drug induced, as can the treatment for these conditions. With infectious colitis, ...

*Pseudopolyps

Ulcerative Colitis: Pseudopolyps; http://www.endoatlas.com/ib_uc_03.html http://bjr.birjournals.org/content/51/610/782.full.pdf ...

*Alosetron

Crohn's disease or ulcerative colitis; diverticulitis; severe hepatic impairment. Concomitant use of fluvoxamine is also ... The FDA said it had reports of 49 cases of ischemic colitis and 21 cases of "severe constipation" and that ten of the 70 ... Severe adverse events continued to be reported, with a final total of 84 instances of ischaemic colitis, 113 of severe ... The cumulative incidence of ischaemic colitis was 2 in 1000, while serious complications arising from constipation (obstruction ...

*Bronchiectasis

Inflammatory bowel disease, especially ulcerative colitis. It can occur in Crohn's disease as well, but does so less frequently ... Ferguson HR, Convery RP (2002). "An unusual complication of ulcerative colitis". Postgrad. Med. J. 78 (922): 503. doi:10.1136/ ...

*Gastrointestinal wall

Ulcerative colitis involves the colonic mucosa. Crohn's disease may produce inflammation in all layers in any part of the ...

*Cuthbert Dukes

Counsell PB, Dukes CE (1952). "The association of chronic ulcerative colitis and carcinoma of the rectum and colon". The ... Dukes CE (1954). "The surgical pathology of ulcerative colitis". Annals of the Royal College of Surgeons of England. 14 (6): ... Dukes CE, Lockhart-Mummery HE (1957). "Practical points in the pathology and surgical treatment of ulcerative colitis: a ...

*Ileo-anal pouch

Ulcerative colitis is "cured" if the large intestine is removed and the patient has the pouch created, as UC is only located in ... "Proctocolectomy without ileostomy for ulcerative colitis". Br Med J. 2: 85-8. doi:10.1136/bmj.2.6130.85. PMC 1605901 . PMID ... Diseases and conditions of the large intestine which may require surgical removal include: Ulcerative colitis Crohn's disease ( ... In some cases where the pouch was formed to manage colitis, inflammation can return to the pouch in a similar way to the ...

*Surgical extirpation

Ulcerative colitis at eMedicine Neri V; Ambrosi A; Fersini A; Tartaglia N; Valentino TP (2007). "Antegrade dissection in ... Extirpation of the colon, or colectomy, is used in the treatment of patient's ulcerative colitis whose condition is resistant ... Kornbluth A, Sachar DB (2004). "Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology ...

*Neutrophil extracellular traps

NETs have also been reported in the colon mucosa of patients with the inflammatory bowel disease ulcerative colitis. NETs have ... "Neutrophil Extracellular Traps in Ulcerative Colitis". Inflammatory Bowel Diseases. 21 (9): 2052-2067. doi:10.1097/mib. ... Clark, SR; Guy CJ; Scurr MJ; Taylor PR; Kift-Morgan AP; Hammond VJ; Thomas CP; Coles B; Roberts GW; Eberl M; Jones SA; Topley N ...

*Fecal microbiota transplant

... this generally appears to not be the case with ulcerative colitis. Published experience of ulcerative colitis treatment with ... However, in the case of other conditions such as ulcerative colitis, no single culprit has yet been identified.[citation needed ... doi:10.1016/s0140-6736(89)91183-5. Borody T; Warren E; Leis S; Surace R; Ashman O (2003). "Treatment of ulcerative colitis ... Since that time, a number of publications have reported the successful treatment of ulcerative colitis with FMT, with clinical ...

*Golimumab

Löwenberg, Mark; de Boer, Nanne KH; Hoentjen, Frank (2014-03-12). "Golimumab for the treatment of ulcerative colitis". Clinical ... in 2013 for the treatment of ulcerative colitis. Large, double-blind randomized controlled trials in patients with rheumatoid ...

*Adalimumab

... may be effective and well tolerated in ulcerative colitis. It has been approved by the FDA for treatment of moderate ... Although only approved for ulcerative colitis from late 2012 by the FDA in the disease's management, it had been used for ... "FDA approves Humira to treat ulcerative colitis". U.S. Food and Drug Administration. Sep 28, 2012. Croom, Katherine F; ... ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and juvenile idiopathic arthritis. In rheumatoid arthritis, ...

*Human feces

For example, fecal calprotectin levels indicate an inflammatory process such as Crohn's disease, ulcerative colitis and ... and ulcerative colitis. The same color change can be observed after consuming foods that contain a substantial proportion of ... "Fecal hydrogen sulfide production in ulcerative colitis". The American Journal of Gastroenterology. 93 (1): 83-7. doi:10.1111/j ... Celiac disease Crohn's disease Ulcerative colitis Chronic pancreatitis Cystic fibrosis Intestinal infection, e.g. Clostridium ...

*Tenderness (medicine)

Ulcerative colitis Ulcerative colitis causes swelling in the large intestine and can lead to cramping, diarrhea, and more. ...

*Darren Fletcher

Omstein, David (5 February 2014). "Man United's Darren Fletcher explains ulcerative colitis illness". BBC Sport. Retrieved 4 ... revealed in December 2011 to be ulcerative colitis. He made his first Premier League appearance of the season four days later ... career was disrupted by an extended break from football due to continuing health problems caused by ulcerative colitis. Between ... announced that he would be taking an extended break from football following medical advice about his ongoing ulcerative colitis ...

*Second Genome

The company's first foray into drug development was a small molecule treatment for ulcerative colitis (SGM-1019). The mechanism ... Timmerman 2016 refers to indication being ulcerative colitis; Lash 2015 refers to indication being Crohns' disease. Koberstein ...

*Ozanimod

"Efficacy and Safety Study of RPC1063 in Ulcerative Colitis". ClinicalTrials.gov. Cohen, Jeffrey A; Arnold, Douglas L; Comi, ... Touchstone is a double-blind, placebo controlled phase II clinical for the treatment of ulcerative colitis. (NCT01647516). 197 ... Sandborn, W. (2016). "Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis". New England Journal of Medicine. ... and ulcerative colitis (UC). It acts as a sphingosine-1-phosphate (S1P) receptor agonist, sequestering lymphocytes to ...

*Etrolizumab

... for ulcerative colitis: the new kid on the block? Expert Opin Biol Ther. 2016 Apr;16(4):567-72. PMID 26914639 ... As of 2016 it was in phase III studies for induction and maintenance therapy in people with ulcerative colitis and Crohn's. ... Etrolizumab (rhuMAb Beta7) is a biopharmaceutical drug candidate being developed for the treatment of ulcerative colitis and ... Etrolizumab for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2015 Dec 2;12:CD011661. PMID 26630451 ...

*Mitchell Sogin

They study pouchitis, a model for ulcerative colitis. Dr. Sogin also serves on the editorial boards of the Journal of ...

*Johnny Carver (sports author)

He began writing the book in high school after he lost his playing career to ulcerative colitis. The book was publicly praised ... Carver has struggled with health complications, and has been hospitalized frequently with ulcerative colitis, which caused him ...
The proliferative activity and polyamine levels of the rectal epithelium in unoperated ulcerative colitis patients and in ulcerative colitis patients after total colectomy and ileorectal anastomosis were determined and compared with control subjects. Cell proliferation was evaluated in rectal biopsies by in vitro 3H thymidine incorporation by measuring the labeling index and the position of labeled cells along the crypt; polyamines were determined with a chromatographic method. In ulcerative colitis patients the labeling index was significantly increased, and labeled cells were shifted toward the upper part of the crypt when compared with controls. Ileorectal anastomosis patients showed a normalization of the labeling index and a distribution of labeled cells similar to controls. Polyamine levels were also increased in ulcerative colitis patients; in ileorectal anastomosis patients, the level of polyamines was decreased in respect to unoperated patients and return to normal values except for ...
Background: It remains controversial whether or not cytomegalovirus infection in patients with active ulcerative colitis reflects a nonpathogenic colonization or a pathogenic disease warranting antiviral therapy. Goals: The aim of this study was to determine the prevalence of cytomegalovirus infection in patients with active ulcerative colitis and the therapeutic efficacy of ganciclovir against cytomegalovirus infection in patients with steroid-refractory ulcerative colitis. Study: A prospective, multicenter study was conducted in 72 patients with moderate-to-severe ulcerative colitis who were treated with intravenous steroids. The presence of cytomegalovirus was evaluated serologically and histopathologic examination, including immunohistochemical staining. In patients with steroid-refractory ulcerative colitis, cytomegalovirus infections were treated with intravenous ganciclovir. In patients with steroid-responsive ulcerative colitis, steroid therapy was continued irrespective of ...
There is increasing evidence that ulcerative colitis is associated with an abnormality of the immune system. Although the aetiology remains unknown, it has been suggested that the immune system of these patients is implicated in the pathogenesis of their disease. T cell function was investigated in ulcerative colitis patients and defective phytohaemagglutinin induced T cell mitogenesis was found. The DNA synthesis induced by stimulation with phorbol esters plus ionophore (ionomycin), however, was normal. These changes cannot be ascribed to either decreased interleukin 2 synthesis or to a defective interleukin 2 receptor expression after cellular activation. Moreover, this defective proliferative response of the T lymphocytes was observed even in the presence of saturated concentrations of exogenous interleukin 2. These results emphasise that the interleukin 2 dependent proliferation pathway is deficient in T lymphocytes from ulcerative colitis patients.. ...
Ulcerative colitis is an inflammatory bowel disease that is a chronic autoimmune disorder of the colon. Despite the best medical management, ulcerative colitis patients often experience episodic flare-ups with symptoms that include abdominal pain, diarrhea, and rectal bleeding. Flare-ups are sometimes triggered by stress, and there is a great deal of interest in stress-reduction interventions that might improve quality of life and reduce flare-ups, and defining those ulcerative colitis subpopulations that might benefit most from such techniques.. Jedel et al. [Digestion] studied MBSRs effectiveness in preventing ulcerative colitis flare-ups in a randomized, double-blind study. Fifty-five moderately severe ulcerative colitis patients in remission were assigned to either MBSR or a placebo (lectures and videos on mind/body medicine). Moderate severity of disease status was defined by a Mayo Ulcerative Colitis Disease Activity Index of 6-12. Measures taken at baseline, post-treatment, and 6 and ...
1. To investigate the role of interleukin-1β in chronic ulcerative colitis, we quantified interleukin-1β steady-state release into the colonic lumen.. 2. We studied 26 patients with untreated chronic ulcerative colitis and seven patients with irritable bowel syndrome who served as disease controls. In seven ulcerative colitis patients, the disease was inactive and in 19 it was mild to moderately active, according to clinical and colonoscopic criteria. Seven patients with active colitis were studied before and after 4 weeks of treatment with oral 5-aminosalicylic acid.. 3. Colonic perfusions were performed using a double-lumen technique. An isotonic solution was continuously infused 50 cm from the anal verge at 5 ml/min, and was recovered 30 cm distally by siphonage. Interleukin-1β was measured by ELISA, polymorphonuclear elastase by immunoactivation and leukotriene B4 by specific RIA.. 4. All control patients and five out of seven patients with inactive colitis had undetectable ...
TY - JOUR. T1 - Clinical differences between elderly-onset ulcerative colitis and non-elderly-onset ulcerative colitis. T2 - A nationwide survey data in Japan. AU - Komoto, Shunsuke. AU - Higashiyama, Masaaki. AU - Watanabe, Chikako. AU - Suzuki, Yasuo. AU - Watanabe, Mamoru. AU - Hibi, Toshifumi. AU - Takebayashi, Toru. AU - Asakura, Keiko. AU - Nishiwaki, Yuji. AU - Miura, Soichiro. AU - Hokari, Ryota. PY - 2018/1/1. Y1 - 2018/1/1. N2 - Background and Aim: Studies on the characteristics of elderly-onset ulcerative colitis (EOUC) and non-elderly-onset ulcerative colitis (NEOUC) have reported conflicting findings. The aim of this study was to compare disease characteristics of EOUC and NEOUC by analyzing the database of the Japanese nationwide inflammatory bowel disease (IBD) registry. Methods: We analyzed the age of disease onset, sex, disease severity, and disease extent in patients with ulcerative colitis that were newly diagnosed and registered within 1 year between 2004 and 2009 (n = 28 ...
Ulcerative Colitis Market by Molecule Type (Biologics and Small Molecules), by Disease Type (Mild Ulcerative Colitis, Moderate Ulcerative Colitis, Severe Ulcerative Colitis), by Route of Administration (Oral and Injectables) - Global Opportunity Analysis and Industry Forecast, 2017-2023
Review Question We reviewed the evidence about the effects and safety of methotrexate for maintaining remission in patients with ulcerative colitis, with the medical literature up to June 26, 2014.. Background What is ulcerative colitis?. Ulcerative colitis is a chronic inflammatory bowel disease characterized by recurrent episodes of active disease, which commonly affect the rectum or colon or both. Patients with active disease may experience abdominal cramping, urgency to pass stools, and bloody diarrhea. When the symptoms stop, patients are considered to be in remission.. What is methotrexate?. Methotrexate is a medication that reduces the bodys immune responses and may reduce inflammation associated with ulcerative colitis.. Study Characteristics The researchers identified three studies that included a total of 165 patients. One study (67 patients) compared oral methotrexate (12.5 mg/week) to placebo (e.g. a sugar pill or fake medicine), one study (26 patients) compared oral methotrexate ...
Pancolitis or universal colitis is a very severe form of ulcerative colitis. This form of ulcerative colitis is spread throughout the entire large intestine including the right colon, the left colon, the transverse colon, descending colon, and the rectum. A diagnosis can be made using a number of techniques but the most accurate method is direct visualization via a colonoscopy. Symptoms are similar to those of ulcerative colitis but more severe and affect the entire large intestine. Patients with ulcerative colitis generally exhibit symptoms including rectal bleeding as a result of ulcers, pain in the abdominal region, inflammation in varying degrees, and diarrhea (often containing blood). Pancolitis patients exhibit these symptoms and may also experience fatigue, fever, and night sweats. Due to the loss of function in the large intestine patients may lose large amounts of weight from being unable to procure nutrients from food. In other cases the blood loss from ulcers can result in anemia ...
Background: Crohns disease and ulcerative colitis are the two major forms of inflammatory bowel disease; treatment strategies have historically been determined by this binary categorisation. Genetic studies have identified 163 susceptibility loci for inflammatory bowel disease, mostly shared between Crohns disease and ulcerative colitis. We undertook the largest genotype association study, to date, in widely used clinical subphenotypes of inflammatory bowel disease with the goal of further understanding the biological relations between diseases.. Methods This study included patients from 49 centres in 16 countries in Europe, North America, and Australasia. We applied the Montreal classification system of inflammatory bowel disease subphenotypes to 34,819 patients (19,713 with Crohns disease, 14,683 with ulcerative colitis) genotyped on the Immunochip array. We tested for genotype-phenotype associations across 156,154 genetic variants. We generated genetic risk scores by combining information ...
291579307 - EP 1257563 A1 2002-11-20 - THERAPEUTIC AND DIAGNOSTIC METHODS FOR ULCERATIVE COLITIS AND ASSOCIATED DISORDERS - [origin: WO0158927A1] This invention relates to the field of therapy and diagnostic methods for ulcerative colitis. Specifically, the method comprises administering a compound or recombinant protein that inhibits interaction between CEP and human tropomyosin. Also included in the invention are methods to screen for drugs useful in treating ulcerative colitis and diagnostic methods for detecting diseases associated with an autoantigen response to hTM in affected tissue.[origin: WO0158927A1] This invention relates to the field of therapy and diagnostic methods for ulcerative colitis. Specifically, the method comprises administering a compound or recombinant protein that inhibits interaction between CEP and human tropomyosin. Also included in the invention are methods to screen for drugs useful in treating ulcerative colitis and diagnostic methods for detecting diseases associated
BACKGROUND The treatment of severe ulcerative colitis (UC) flares includes measures such as hospitalization and intravenous steroids. Despite this, a quarter of patients are refractory to treatment. Given the availability of new therapeutic strategies in patients with steroid-refractory UC (cyclosporine, infliximab, apheresis, surgery) it is necessary to predict which treatment will be most effective for each patient. OBJECTIVES To determine which clinical or biological factors discriminate the lack of response to cyclosporine in steroid-refractory UC. METHODS Forty one flares of steroid-refractory UC in 35 patients treated with intravenous cyclosporine have been included. The response to cyclosporine was assessed at day 10 of treatment by using the modified Truelove and Witts disease activity score. Variables with prognostic significance were determined by a univariate analysis comparing groups with complete response and no-response, and an analysis of multiple linear regression. RESULTS Complete
MOKHELE, N N; THOMSON, S R and WATERMEYER, G A. Predictors of emergency colectomy in patients admitted with acute severe ulcerative colitis. S. Afr. j. surg. [online]. 2017, vol.55, n.3, pp.20-26. ISSN 2078-5151.. BACKGROUND: Acute Severe Ulcerative Colitis (ASUC) is a life-threatening condition which requires urgent and aggressive medical therapy to reduce mortality, morbidity and avoid surgery. To facilitate this process, it is essential to identify patients at high risk of poor outcomes and emergency colectomy. Numerous such risk factors have been described in Western literature, however there is no local data addressing this issue. As such it is unclear if these predictors are applicable in our setting. The aim of this study is thus to identify risk factors for emergency colectomy in patients admitted to Groote Schuur Hospital with ASUC. METHODS: A retrospective cohort study of 98 patients admitted with ASUC between January 2003 and January 2013 was performed. Clinical, demographic, ...
... Annals of Internal Medicine, Volume 112, Number 6, 15 March, 1990, p. 471. To the Editor: The apparent protective effect of cigarette smoking on ulcerative colitis (1) suggests that inhaled plant products might affect the disease process. We report a case suggesting a relation between ulcerative colitis and smoking marijuana. In 1972, a 23-year-old woman developed abdominal pain, diarrhea, and rectal bleeding. Sigmoidoscopy to 15 cm revealed diffuse cobblestone ulcerations, and a single-contrast barium enema showed numerous small marginal irregularities in the distal sigmoid and rectum. Ulcerative colitis was diagnosed, and her symptoms waxed and waned despite treatment with sulfasalazine, librax, and intermittent prednisone. Discouraged, she stopped all medications in 1975. In 1976, she noted that smoking marijuana resulted in fewer stools, more stable body weight, and fewer, milder exacerbations . Her typical intake was a pipeful once or twice daily, which she ...
BACKGROUND: The mechanisms underlying the frequent development of colorectal carcinomas in patients with ulcerative colitis are still unknown. AIMS: To evaluate whether mucosal necrosis and regeneration act as enhancing or promoting factors in colorectal tumorigenesis, development of multiple colorectal tumours was studied in a murine model of ulcerative colitis with azoxymethane pretreatment. METHODS: Periods of chronic ulcerative colitis in mice were induced by three repeated administrations of 3% dextran sulphate sodium subsequent to a single azoxymethane pretreatment, to give conditions similar to the clinically observed active and remission phases. RESULTS: In the chronic colitis group with carcinogen exposure, multiple mucosal tumours (10.5/mouse) developed in the colorectum. This occurred primarily on the left side of the large intestine or transverse colon, the sites of the most severe colitic injury. The observed lesions were high grade dysplasias and invasive adenocarcinomas. Increased ...
Management of ulcerative colitis involves first treating the acute symptoms of the disease, then maintaining remission. Ulcerative colitis is a form of colitis, a disease of the intestine, specifically the large intestine or colon, that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually diarrhea mixed with blood, of gradual onset which often leads to anaemia. Ulcerative colitis is, however, a systemic disease that affects many parts of the body outside the intestine. Standard treatment for ulcerative colitis depends on extent of involvement and disease severity. The goal is to induce remission initially with medications, followed by the administration of maintenance medications to prevent a relapse of the disease. The concept of induction of remission and maintenance of remission is very important. The medications used to induce and maintain a remission somewhat overlap, but the treatments are different. Physicians first direct treatment to ...
We report a 34-year-old man with chronic hepatitis C who showed exacerbation of ulcerative colitis during alpha-interferon (IFNα) therapy. Discontinuance of the IFNα therapy improved his symptoms, suggesting that IFNα administration might worsen ulcerative colitis. The administration of sulfasalazine allowed the patient to receive IFNα again without flare-up of ulcerative colitis. This case suggests the possible efficacy of sulfasalazine therapy in patients with ulcerative colitis complicated by some other diseases requiring IFNα administration ...
Poor appetite, diarrhea, and poor digestion of nutrients can make it hard for people with ulcerative colitis to get the calories and nutrients the body needs.. Kids and teens with ulcerative colitis should eat a variety of foods, get plenty of fluids, and learn to avoid foods that make symptoms worse. Some may need supplements, like calcium or vitamin D. Kids who are not growing well may need additional nutrition support.. Kids and teens with ulcerative colitis can feel different and might not be able to do the things their friends can do, especially during flare-ups. Some struggle with a poor self-image, depression, or anxiety. They may not take their medicine or follow their diet. Its important to talk to your health care professional if youre concerned about your childs mood, behavior, or school performance.. Parents can help teens with ulcerative colitis take on more responsibility for their health as they get older.. Reviewed by: J. Fernando del Rosario, ...
Although many theories about what causes ulcerative colitis exist, none has been proven. The cause of ulcerative colitis is unknown, and currently there is no cure, except through surgical removal of the colon. A theory suggests that some agent, possibly a virus or an atypical bacterium, interacts with the bodys immune system to trigger an inflammatory reaction in the intestinal wall.. Although much scientific evidence shows that people with ulcerative colitis have abnormalities of the immune system, doctors do not know whether these abnormalities are a cause or result of the disease.. There is little proof that ulcerative colitis is caused by emotional distress or sensitivity to certain foods or food products, or is the result of an unhappy childhood.. ...
Although many theories about what causes ulcerative colitis exist, none has been proven. The cause of ulcerative colitis is unknown, and currently there is no cure, except through surgical removal of the colon. A theory suggests that some agent, possibly a virus or an atypical bacterium, interacts with the bodys immune system to trigger an inflammatory reaction in the intestinal wall.. Although much scientific evidence shows that people with ulcerative colitis have abnormalities of the immune system, doctors do not know whether these abnormalities are a cause or result of the disease.. There is little proof that ulcerative colitis is caused by emotional distress or sensitivity to certain foods or food products, or is the result of an unhappy childhood.. ...
Although many theories about what causes ulcerative colitis exist, none has been proven. The cause of ulcerative colitis is unknown, and currently there is no cure, except through surgical removal of the colon. A theory suggests that some agent, possibly a virus or an atypical bacterium, interacts with the bodys immune system to trigger an inflammatory reaction in the intestinal wall.. Although much scientific evidence shows that people with ulcerative colitis have abnormalities of the immune system, doctors do not know whether these abnormalities are a cause or result of the disease.. There is little proof that ulcerative colitis is caused by emotional distress or sensitivity to certain foods or food products, or is the result of an unhappy childhood.. ...
Ulcerative Colitis, Read about Ulcerative Colitis symptoms, causes, diagnosis, and treatment. Also read Ulcerative Colitis articles about how to live with Ulcerative Colitis, and more.
To test the suggestion that an inherited defect in colonic mucus rendering it susceptible to degradation by bacterial enzymes may be an important factor in the aetiology of ulcerative colitis, 650 colonoscopic and rectal biopsy specimens from 166 patients with colitis were stained by mild periodic acid Schiff (mPAS), which shows sialic acid that is deficient in O-acetyl substituents. There was an excess of mPAS positive sialic acid in patients with chronic ulcerative colitis, but the increased expression was patchy and coincided with a morphological change in the form of epithelial hyperplasia (metaplasia). Hyperplasia was more common in the rectum and in women and was associated with, and presumably secondary to, active inflammation. It is concluded that variation in the structure of sialic acid is acquired and is therefore unlikely to be implicated in the aetiology of ulcerative colitis.
Santarus, a specialty pharmaceutical company, has begun patient enrollment in phase IIIb clinical study with the investigational drug Uceris (budesonide) tablets 9mg in combination with current oral aminosalicylate (5-ASA) therapy for patients with active ulcerative colitis.. Uceris is a locally acting (non-systemic) corticosteroid in an oral tablet formulation and is designed for controlled release and distribution of budesonide, which has a topical anti-inflammatory activity, throughout the length of the colon.. The multicenter, randomized, double-blind, placebo-controlled study will evaluate patients with mild or moderate active ulcerative colitis who continue using their current 5-ASA treatment regimen and for an eight-week period add either Uceris 9mg or placebo administered once daily. The primary endpoint of the study will be remission at week eight, defined as an Ulcerative Colitis Disease Activity Index (UCDAI) score of less than or equal to one, with a zero score for rectal bleeding, ...
Ulcerative colitis is characterized by chronic inflammation of the colon. Typical symptoms are diarrhoea, rectal bleeding, abdominal pain and fever. The aetiology of the disease is unclear. The inflammation can be localized in the rectum or can extend to the left side or the whole colon. Treatment for induction and remission maintenance depends on the severity and extension of mucosal inflammation. Topical 5-aminosalicylates have been shown in studies to be the treatment of choice in mild to moderate ulcerative colitis. Oral 5-aminosalicylates can be used in distal, mild and moderate ulcerative colitis and for remission maintenance. For patients with a more extended or severe inflammation, oral or i.v. corticosteroids should be used. Patients with severe and/or chronic disease require immunosuppressive therapy with azathioprine or 6-mercaptopurine. For patients with severe, chronic, refractory disease, cyclosporine i.v. can be used. If no response to treatment is seen, proctocolectomy should be ...
A diagnosis of Crohns disease (CD) and ulcerative colitis (UC) is based on a combination of clinical, histologic, endoscopic, and radiologic data. The distinction between UC and CD can be difficult because of the lack of a differentiating single gold standard. Indeterminate colitis (IC) was introduced by pathologists for the diagnosis of surgical colectomy specimens showing an overlap between the features of UC and CD. The diagnosis of IC was based on macroscopic and microscopic features. The term indeterminate colitis is in recent years more widely applied to include all cases with endoscopic, radiographic, and histologic evidence of chronic inflammatory bowel disease confined to the colon, but without fulfilment of diagnostic criteria for UC and CD. As for UC and CD, the diagnosis of IC has therefore become a clinicopathologic diagnosis. IC is generally considered to be a temporary diagnosis. The clinical characteristics of patients with IC are, however, somewhat different from the ...
In most cases, you will need to see a colon and rectal specialist to confirm a diagnosis of either Crohns disease or ulcerative colitis. Many general practitioners are unfamiliar with these conditions, and they are typically hard to differentiate without further testing due to their similar symptoms. To further complicate matters, about ten percent of patients have a condition known as indeterminate colitis, in which the diagnostic features of both Crohns disease and ulcerative colitis are present.. Several tests are typically used to diagnose Crohns, colitis or other forms of IBS. Blood tests and laboratory tests on a stool sample are often first, with endoscopic tests to follow. Depending on the symptoms, your doctor will either perform an upper endoscopy or a colonoscopy.. An upper endoscopy requires inserting a flexible tube equipped with a camera through the mouth and into the gastrointestinal tract. This test gives the doctor a look at the upper GI area, as far down as the duodenum, the ...
Objectives: To examine biopsy specimens for histologic features suggestive of Clostridium difficile infection in patients with ulcerative colitis (UC). Methods: Nine patients with UC had colonic biopsy specimens taken during a symptomatic flare that coincided with positive C difficile (C difficile+) tests. Twenty-eight controls were biopsied during a UC flare but tested negative for C difficile. We reviewed the slides for evidence of pseudomembranes, ischemic-like changes, degree of colitis, and lamina propria hemorrhage. Results: In C difficile+ patients, 4 (44.4%) of 9 had microscopic pseudomembranes compared with 11% in controls (P < .05). Other histologic/clinical features were not predictive. Conclusions: Although the presence of microscopic pseudomembranes suggests C difficile infection in patients with UC, sensitivity and specificity are poor; biopsy findings do not reliably detect this infection in patients with UC ...
Background: Patients with ulcerative colitis and Crohns colitis are at increased risk of colon cancer. The usefulness of chromoendoscopy is debated. Previous studies are either based on magnifying endoscopy or on non-randomized trials. Some guidelines recommend chromoendoscopy with targeted biopsies and some normal colonoscopy with up to 40 random biopsies.. Chromoendoscopy has the ability to identify subtle lesions that are otherwise missed by standard endoscopy. Whether chromoendoscopy with targeted biopsies can replace standard colonoscopy with random biopsies in the surveillance of patients with chronic colitis is unknown.. Aim: In a RCT in surveillance colonoscopies in patients with ulcerative colitis or Crohns colitis, we will determine if chromoendoscopy using a dilute solution of Indigo-carmine will improve dysplasia detection rate compared with colonoscopy without chromoendoscopy.. Methods: After informed consent patients undergoing surveillance colonoscopy will be randomized to be ...
To cast light on the contribution of methylation to genesis of ulcerative colitis (UC)-associated tumors, promoter methylation and expression of O6-methylguanine DNA methyltransferase (MGMT), hMLH1, p16INK4, and E-cadherin were examined in 14 low-grade dysplasias (LGDs), 15 high-grade dysplasias (HGDs), and 14 adenocarcinomas associated with UC and, for comparison, in 30 sporadic adenomas with LGD, 30 adenomas with HGD, and 60 adenocarcinomas, using methylation-specific polymerase chain reaction and immunohistochemical analysis. The frequency of MGMT and hMLH1 methylation in UC-associated tumors was low, with a significant difference between HGD and sporadic adenomas with HGD of the left hemicolon. The methylation frequency of p16INK4 in UC-associated tumors was also relatively low compared with sporadic colonic tumors. For E-cadherin, methylation was limited in both types of tumor. Decrease of expression of MGMT, hMLH1, and p16INK4 was significantly correlated with methylation. Thus, compared ...
Background Recent metagenomic analyses have revealed dysbiosis of the gut microbiota of ulcerative colitis (UC) patients. However, the impacts of this dysbiosis are not fully understood, particularly...
By Jennifer CashNEW YORK (Reuters Health) - Some forms of inflammatory bowel disease are a bigger threat to pregnancy than others, suggests a large new U.S. analysis.One of two major types of IBD, ulcerative colitis, was most strongly linked to serious pregnancy complications, researchers found in a study of nearly 400,000 women.But all women with IBD can and should take precautions for a safe pregnancy, experts said.A sick mother is not good for a growing pregnancy, Dr. Shannon Clark, an obstetrician in the Division of Maternal-Fetal Medicine at the University of Texas Medical Branch at Galveston, told Reuters Health by email.Crohns Disease and ulcerative colitis are the main forms of IBD. Both affect the digestive tract, although the Crohns and Colitis Foundation of America defines ulcerative colitis as a chronic disease of the large intestine, while Crohns disease is a chronic inflammatory condition of the entire gastrointestinal tract.The causes of ulcerative colitis and Crohns disease remain
If you did not respond to a medication regimen or you developed complications of colitis, you may be a candidate for surgery to treat ulcerative colitis.. Colectomy (removing part or the entire colon) may be used in children with ulcerative colitis who experienced growth retardation. In all patients, elective colectomy can be a cure for ulcerative colitis. Almost always, the procedure is a total colectomy, meaning the entire colon is removed.. Surgical procedures include:. ...
Surgery If diet and lifestyle changes, medications or other treatments do not relieve your symptoms, your doctor may recommend surgery. Surgery can often eliminate ulcerative colitis, but that usually means removing your entire colon and rectum. Lifestyle Changes to Treat Ulcerative Colitis You can make dietary and lifestyle changes to help alleviate symptoms and lengthen time between flare-ups. While there is no evidence that says certain foods cause ulcerative colitis, there are certain foods that can aggravate your symptoms. Limiting dairy products and avoiding problem foods may help improve your symptoms. Problems foods can vary for each person, but you should also avoid "gassy" foods such as beans, cabbage and broccoli, raw fruits and fruits, popcorn, caffeine and carbonated beverages. Experiment with fiber. For some, adding more high-fiber foods can help with bowel issues; however, if you have an inflammatory bowel disease fiber may worsen your symptoms. Try eating five or six meals ...
Surgery If diet and lifestyle changes, medications or other treatments do not relieve your symptoms, your doctor may recommend surgery. Surgery can often eliminate ulcerative colitis, but that usually means removing your entire colon and rectum. Lifestyle Changes to Treat Ulcerative Colitis You can make dietary and lifestyle changes to help alleviate symptoms and lengthen time between flare-ups. While there is no evidence that says certain foods cause ulcerative colitis, there are certain foods that can aggravate your symptoms. Limiting dairy products and avoiding problem foods may help improve your symptoms. Problems foods can vary for each person, but you should also avoid "gassy" foods such as beans, cabbage and broccoli, raw fruits and fruits, popcorn, caffeine and carbonated beverages. Experiment with fiber. For some, adding more high-fiber foods can help with bowel issues; however, if you have an inflammatory bowel disease fiber may worsen your symptoms. Try eating five or six meals ...
This study is designed to investigate the safety and effectiveness of infliximab in adult patients with active ulcerative colitis. The purpose of this study is to see if the symptoms of ulcerative colitis are lessened with this medication infliximab, and what dose is needed to do that safely.Patients will receive infusions of either 5 or 10 mg/kg or placebo at weeks 0, 2, 6, 14, and 22 up to week 164. Safety evaluations will be performed at specified intervals throughout the study and will consist of laboratory tests, vital signs (such as blood pressure), physical examinations and the occurrence and severity of adverse events as well as other study specific procedures.. Patients will receive infusions (into the vein) of either 5 or 10 mg/kg or placebo at weeks 0, 2, 6, and every 8 weeks up to week 164. ...
Ulcerative colitis is a form of inflammatory bowel disease. The symptoms of ulcerative colitis may include bloody diarrhea, tenesmus, malaise, anorexia, loss of weight, fecal urgency and mucus discharge.
TY - JOUR. T1 - A cross-ethnic survey of CFB and SLC44A4, Indian ulcerative colitis GWAS hits, underscores their potential role in disease susceptibility. AU - Gupta, Aditi. AU - Juyal, Garima. AU - Sood, Ajit. AU - Midha, Vandana. AU - Yamazaki, Keiko. AU - Vich Vila, Arnau. AU - Esaki, Motohiro. AU - Matsui, Toshiyuki. AU - Takahashi, Atsushi. AU - Kubo, Michiaki. AU - Weersma, Rinse K.. AU - Thelma, B. K.. PY - 2016/1/1. Y1 - 2016/1/1. N2 - The first ever genome-wide association study (GWAS) of ulcerative colitis in genetically distinct north Indian population identified two novel genes namely CFB and SLC44A4. Considering their biological relevance, we investigated allelic/genetic heterogeneity in these genes among ulcerative colitis cohorts of north Indian, Japanese and Dutch origin using high-density ImmunoChip case-control genotype data. Comparative linkage disequilibrium profiling and test of association were performed. Of the 28 CFB SNPs, similar strength of association was observed for ...
Doctor answers on Symptoms, Diagnosis, Treatment, and More: Dr. Hoepfner on nursing diagnosis for ulcerative colitis: There are several new agents such as remicaid that may be used. Surgery is also a good option for ulcerative colitis. Fecal transplant has also been reported to be effective. You should discuss these options with your doctor. For topic: Nursing Diagnosis For Ulcerative Colitis
Herbal treatment of ulcerative colitis Phytotherapy: Medicinal plants preparations for ulcerative colitis Phytotherapy in the treatment of ulcerative colitis must be made by mutual agreement between the patient and the doctor to whom it must be communicated the willingness to adopt any of these th
Lee Rannals for redOrbit.com - Your Universe Online. People suffering from ulcerative colitis may be getting some new relief due to a decision by the Food and Drug Administration (FDA) to expand the use of a new drug to help alleviate symptoms.. An FDA panel voted 15 to 2 that the benefits of Humira outweighed the risks it causes when treating the condition.. Humira is already approved to be used for six other conditions, and is most popular for its use to help in rheumatoid arthritis and Crohns disease patients.. The FDA panel is made of up of outside advisers to the agency, and the agency itself doesnt have to follow the panels suggestions. However, it normally does, and a final decision on Humira is expected to be made by the end of the year.. The drug is one of the worlds top-selling drugs, and is projected to bring in $9 billion in sales this year.. Drug maker Abbott Laboratories is wanting to expand the use of Humira to ulcerative colitis, which is a chronic disease that can cause ...
Background: Inflammatory bowel disease, an autoimmune disease, has two clinical manifestations including Crohns disease and ulcerative colitis (UC). IL-17 has been the target of intensive research in autoimmune diseases. The influence of Toll like receptor 4 (TLR-4) gene polymorphisms on IL-17 production has also been revealed in UC patients and tissue inflammation in mice. Objectives: To investigate the association between the TLR-4 gene polymorphisms, Asp299Gly and Thr399Ile and IL-17 serum levels with ulcerative colitis. Additionally, we aimed to study modulation effects of forenamed gene polymorphisms on IL-17 serum levels in UC patients and controls. Methods: A total of 256 healthy controls and 85 UC patients enrolled in our study. DNA was extracted and PCR-RFLP technique was employed to determine Asp299Gly and Thr399Ile polymorphisms in TLR-4 gene and IL-17 serum levels were measured by ELISA method. Results: There was no significant difference between the frequency of Asp299Gly A|G and Thr399Ile
Intestinal dysbiosis in inflammatory bowel disease (IBD) patients depend on disease activity. We aimed to characterize the microbiota after 7 years of follow-up in an unselected cohort of IBD patients according to disease activity and disease severity. Fifty eight Crohns disease (CD) and 82 ulcerative colitis (UC) patients were included. Disease activity was assessed by the Harvey-Bradshaw Index for CD and Simple Clinical Colitis Activity Index for UC. Microbiota diversity was assessed by 16S rDNA MiSeq sequencing. In UC patients with active disease and in CD patients with aggressive disease the richness (number of OTUs, p = 0.018 and p = 0.013, respectively) and diversity (Shannons index, p = 0.017 and p = 0.023, respectively) were significantly decreased. In the active UC group there was a significant decrease in abundance of the phylum Firmicutes (p = 0.018). The same was found in CD patients with aggressive disease (p = 0.05) while the abundance of Proteobacteria phylum showed a significant ...
Gilead Sciences has pulled the plug on a combined Phase II/III clinical study of GS-5745 testing the investigational anti-MMP9 antibody in patients with moderately to severely active ulcerative colitis. - News - PharmaTimes
Ulcerative colitis is an inflammation and ulceration of the rectum which can ascend up through the whole large intestine. The symptoms of ulcerative colitis are mostly chronic diarrhea with blood in the stool. Frequently there is weakness, lack of appetite, pain of the left abdomen, rectal pain and even cramping. We often see mucus in…
DEERFIELD, Ill. - Takeda Pharmaceutical Co. is seeking Food and Drug Administration approval for an experimental treatment for inflammatory bowel disease, the drug maker said. Takeda announced that it had submitted a biologics license application to the FDA for vedolizumab in patients with severe Crohns disease and ulcerative colitis. IBD is estimated to affect more than 4 million people worldwide, and ulcerative colitis and Crohns disease affect as many as 700,000 Americans each, according to Takeda.
Inflammatory bowel disease (IBD) includes two chronic conditions, Crohns disease and ulcerative colitis. It has remained for too long the secret illness no one wants to admit to having, let alone discuss. One percent of North Americans have IBD, yet its cause is unknown, and there is no known cure. Fred Saibil, a renowned expert on IBD, provides concise, critical and practical information on the common symptoms and side effects. He describes the normal gastrointestinal system and then explains what specifically goes wrong in those suffering from IBD. Crohns Disease and Ulcerative Colitis includes important information on: Signs and symptoms Possible complications Procedures and instruments used to diagnose IBD Effects of diet Available drugs and how they work Children and IBD Cancer and IBD Surgical options Effects on sexual activity and childbearing. The book also provides detailed tables, sidebars and diagrams, plus travel tips and other self-help strategies for coping with IBD. For patients, their
Inflammatory bowel disease, or IBD, is a general term that reflects an abnormal immune response resulting in inflammation of the intestinal tract. The two most common forms of IBD are ulcerative colitis and Crohns disease. Both diseases are believed to be caused by an abnormal response in the bodys immune system so that the digestive tract mistakes food and other materials as foreign substances. This stimulates a response to attack the cells of the intestines by sending white blood cells to the area to produce inflammation.. Ulcerative colitis. Ulcerative colitis is a chronic condition that affects the colon or large bowel only and is limited to the inner layer of the colon. The lining of the colon becomes inflamed and develops tiny, open sores (ulcers) that produce pus and mucus.. Symptoms of Ulcerative Colitis. One of the first symptoms of ulcerative colitis is loosening of the stool, which usually is bloody and may be accompanied by abdominal cramping and the severe urge to have a bowel ...
Inflammatory bowel disease, or IBD, is a general term that reflects an abnormal immune response resulting in inflammation of the intestinal tract. The two most common forms of IBD are ulcerative colitis and Crohns disease. Both diseases are believed to be caused by an abnormal response in the bodys immune system so that the digestive tract mistakes food and other materials as foreign substances. This stimulates a response to attack the cells of the intestines by sending white blood cells to the area to produce inflammation.. Ulcerative colitis. Ulcerative colitis is a chronic condition that affects the colon or large bowel only and is limited to the inner layer of the colon. The lining of the colon becomes inflamed and develops tiny, open sores (ulcers) that produce pus and mucus.. Symptoms of Ulcerative Colitis. One of the first symptoms of ulcerative colitis is loosening of the stool, which usually is bloody and may be accompanied by abdominal cramping and the severe urge to have a bowel ...
Treat refractory ulcerative colitis with an anti-tumor necrosis factor agent.. The most appropriate treatment is to initiate an anti-tumor necrosis factor (anti-TNF) agent such as adalimumab. This patient has moderate to severe ulcerative colitis that is not responding to 60 mg/d of prednisone. Moderate to severe ulcerative colitis is often treated with oral glucocorticoids such as prednisone, 40 to 60 mg/d. Patients whose disease does not respond to oral glucocorticoids should be hospitalized and given intravenous glucocorticoids or should be treated with an anti-TNF agent. Randomized controlled clinical trials have shown three anti-TNF antibodies (infliximab, adalimumab, and golimumab) to be effective for inducing and maintaining remission in patients such as this with ulcerative colitis. Indications for hospital admission include dehydration, inability to tolerate oral intake, fever, significant abdominal tenderness, and abdominal distention. A meta-analysis of clinical trials showed that ...
Learn more about Ulcerative Colitis at Blake Medical Center Related Terms Inflammatory Bowel Disease (Ulcerative Colitis, Crohns Disease) Uses Principal ...
High-quality endoscopic and histological diagnoses were available from 1990 to 2003. Ulcerative colitis and Crohns disease were diagnosed from clinical, radiological, endoscopic, and histological examinations according to Lennard-Jones criteria. The researchers found that the prevalence of ulcerative colitis and Crohns disease increased between 1990 and 2003. The team noted no change in the sex and age distribution from 1990 to 1996 compared with 1997 to 2003, both in ulcerative colitis and Crohns. However, patients with ulcerative colitis and with higher education and a professional occupation increased during 1997 to 2003 compared with 1990 to 1996.. The mean age of patients with Crohns disease was significantly younger than that of ulcerative colitis at the time of diagnosis.. The team observed that the ratio of male to female patients was 1.5:1 in ulcerative colitis, and 2.3:1 in Crohns disease, respectively. The mean duration of onset of the disease to diagnosis was 1 year in ...
TY - JOUR. T1 - Is 5-ASA Still the Treatment of Choice for Ulcerative Colitis?. AU - Cottone, Mario. AU - Cottone, Mario. AU - Modesto, Irene. AU - Renna, Sara. AU - Orlando, Ambrogio. PY - 2011. Y1 - 2011. N2 - 5-Amino-salacylic acid (5-ASA) is up to now the treatment of choice in theinduction and maintenance of remission of mild-to-moderate ulcerative colitis(UC). Sulfasalazine, despite similar efficacy, is hampered by more side effects, but in presence of peripheral arthopaties it remains the treatment of choice. Thenew delayed release MMX formulation seems to be promising in reducing compliance problems, but further studies are warranted to show the superiority of new MMXformulation compared with the older formulations of 5-ASA. Some trials evaluated also the efficacy and safety of once-daily dosing of older 5-ASA formulations in maintenance of remission, finding a greater adherence to therapy in the groupgiven the once daily regimen, compared with the classic twice daily groups.Regarding ...
The aim of this thesis is to study treatment of inflammatory bowel disease with respect to an acute severe attack of ulcerative colitis and endoscopic balloon dilation in stricturing Crohns disease.. A retrospective follow-up was made in 158 patients who were given intensive intravenous corticosteroid treatment due a severe, moderate, or mild attack of ulcerative colitis between 1975 and 1982. After 10 years, the colectomy frequency in the severe disease group was 64%, and 49% and28% in the moderate and mild groups, respectively. Severity of the original attack did not influence the subsequent clinical course with respect to colectomy.. In 2005, a controlled Swedish-Danish trial of infliximab as rescue therapy in an acute severe attack of steroid refractory ulcerative colitis showed that colectomy frequencies after 3 months were lower in infliximab-treated patients (29%) compared to placebo-treated patients (67%). After 3 years, a statistically significantly lower colectomy frequency remained ...
A phase II induction study to explore the dose-response relationship, efficacy and safety of AJG511 in patients with active ulcerative colitis.
The FDA on Thursday approved Xeljanz extended release 11 mg and 22 mg tablets for the once daily treatment of adults with moderately to severely active ulcerative colitis, following an inadequate response or intolerance to previous TNF blocker therapy, according to a press release from the manufacturer. “Ulcerative colitis is a chronic inflammatory disease of the colon that can
A recent study conducted by scientists has indicated that aerobic exercise can be a boon or a bane for patients of ulcerative colitis, depending on how it is undertaken.
1. Ulcerative Colitis (UC) is a form of Inflammatory Bowel Disease (IBD). The other main form of IBD is Crohns Disease. IBD is an autoimmune disease which means that the immune system attacks the healthy body cells. 2. Around 146, 000 people in the UK are living with Ulcerative Colitis. 3. UC causes inflammation and ulceration of the…
... is a chronic inflammatory and ulcerative disease of the large intestine (colon). It results in the formation of shallow erosions in the intestinal wall. It is similar to Crohns disease in that the cause is unknown. Its peak incidence is in patients in their 20s to 30s. Onset of the disease after age 60 seems to be associated with more severe colitis. The typical course of ulcerative colitis includes intermittent attacks with periods of complete remission (no symptoms). Common presenting symptoms are rectal bleeding and recurrent bouts of diarrhea. More severe disease is characterized by bouts of fever, abdominal pain, nausea, and more than 6 (bloody) bowel movements a day. Weight loss and low blood counts (anemia) are commonly seen. Evaluation will include history and physical examination. Stools will be tested for presence of occult blood (not visible to the naked eye). A blood count will be performed to look for anemia. Stool cultures will be examined to rule out ...
I thought Id spend some time on hidden illnesses; ones where the person is ill and you may not even know it. Because of my personal relationship with it, Im going to start with ulcerative colitis. Ulcerative colitis is an inflammatory bowel disease or digestive disorder (WebMD lists both). It is related to Crohns Disease,…
How to Manage Ulcerative Colitis During Pregnancy. Early pregnancy symptoms like nausea and indigestion can happen to any pregnant woman, but if you have an inflammatory bowel disease like ulcerative colitis, these symptoms might be signs...
TY - JOUR. T1 - Does one score fit all? Measuring risk in ulcerative colitis. AU - Keller, Deborah S.. AU - Cologne, Kyle G.. AU - Senagore, Anthony J.. AU - Haas, Eric M.. PY - 2015/6/15. Y1 - 2015/6/15. N2 - Background: The American College of Surgeons Surgical Risk Calculator was developed to improve risk stratification and surgical quality but has not been studied at the institutional level for specific disease states, like ulcerative colitis (UC). Methods: UC patients undergoing colorectal resection had predicted risk calculator data compared with actual outcomes for length of stay (LOS), complications, reoperation, and death. Main outcome measures were the difference in actual vs predicted outcomes. Results: Seventy patients were evaluated. The actual and predicted mean LOS was identical, but not representative of the actual LOS picture, which had 10 LOS outliers (14.3%). The actual incidence of any complication (P ,.001) and major complications (P ,.001) was higher than predicted. The ...
... SummaryDiagnosed incident cases of Ulcerative colitis (UC) are expected to increase from 94,303 cases in 2016 to ...
Ulcerative colitis is a chronic inflammatory disease that mainly affects the colon and rectum. Onset of disease is most common between the ages of 15-35 years. There is an observed increased risk of colorectal cancer associated with the disease. The risk is often described to be 2% after 10 years, 8% after 20 years and 18% after 30 years disease.. Since 1977, all known patients with ulcerative colitis in the catchment area of Örnsköldsvik Hospital have been invited to attend a colonoscopic surveillance programme. At endpoint of the studies included in this thesis there were 214 patients that had attended the surveillance programme. The aims of these studies have been to evaluate the efficiency of the surveillance programme, analyse the impact of findings of DNA aneuploidy, and determine the outcome for patients that underwent limited resections instead of complete proctocolectomy. Further, we have studied the long-term outcome for patients who had an early onset of disease and analysed the ...
Crohns and Colitis Canada is proud to launch the annual AbbVie IBD Scholarship Program.. Did you know that Crohns disease and ulcerative colitis are most frequently diagnosed between the ages of 15 and 30, with the typical onset being in the early 20s? A recent study found that 69% of people who had Crohns disease or ulcerative colitis when they were young were delayed in completing their post-secondary education.. The AbbVie IBD Scholarship Program recognizes the obstacles faced by students living with Crohns disease and ulcerative colitis and supports them in rising above their personal challenges in pursuit of their dreams.. Supported by an educational grant from AbbVie, Crohns and Colitis Canada will extend 10 one-time scholarships of $5,000 to students living with Crohns disease and ulcerative colitis who are entering into or currently attending a post-secondary educational institution for the fall semester of 2019. The AbbVie IBD Scholarship is a competitive bursary.. Application ...
hi im29yrs old woman have been diagnosed withh ulcerative colitis over a year ago have been takin my medication and all was goin great then i started to get blood in my stool again and severe pain in m...
Prednisone (prednisolone) reviews by ulcerative colitis patients who have used the steroid to treat their UC symptoms during flare ups.
Background and aim: Persistent stress and life events affect the course of ulcerative colitis (UC) by largely unknown mechanisms. Regulation of epithelial permeability to antigens is crucial for the balance between inflammation and immuno-surveillance, and increased intestinal permeability has been shown in patients with ulcerative colitis. Corticotropin releasing hormone (CRH) has been implicated as an important mediator of stress-induced abnormalities in intestinal mucosal function in animal models. Further cholinergic signalling during stress. has been reported to increase bowel ion secretion in humans and uptake of HRP in rodents via activation of mast cells.. The overall aim of this thesis was to examine the role of CRH-mediated and cholinergic signalling, and their interaction with mast cells and eosinophils, in the regulation of the mucosal barrier function in the normal human colon and in UC. In vivo studies or the use of surgical specimens for such studies have major shortcomings. ...
Physicians make the diagnosis of ulcerative colitis based on the patients clinical history, a physical examination, and a series of tests. The first goal of these tests is to differentiate ulcerative colitis from infectious causes of diarrhea. Accordingly, stool specimens are obtained and analyzed to eliminate the possibility of bacterial, viral, or parasitic causes of diarrhea. Blood tests can check for signs of infection as well as for anemia, which may indicate bleeding in the colon or rectum. Following this, the patient generally undergoes an evaluation of the colon, using one of two tests -- a sigmoidoscopy or total colonoscopy.. To perform a sigmoidoscopy, the doctor passes a flexible instrument into the rectum and lower colon. This test allows the doctor to visualize the extent and degree of inflammation in these areas. A total colonoscopy is a similar exam, but it visualizes the entire colon. Using these techniques, your physician can detect inflammation, bleeding, or ulcers on the ...
Ulcerative colitis is a chronic condition that affects millions of people around the world. Although its cause isnt completely understood, research suggests that bacteria in the gastrointestinal tract play an important part. People with the condition experience repeated inflammation of the large intestines lining, which can cause ulcers, abdominal pain, diarrhea and other symptoms. At least one recent study suggested that vinegar, which has been used in traditional medicine for centuries, might be effective against ulcerative colitis. Lu Yu, Bo Liu and colleagues wanted to further investigate this possibility ...
Exercises are designed from Physique With Dr Charles Livingstons Program. Paleo Diet Recipes For Ulcerative Colitis 2.0 left side abdominal pain may arise gluten free grain free zucchini nut bread london museum ntology a high fever dizziness confusion or a loss of Exercise regularly eat well normal Convert Kilojoules , to Calories . Diabetes weight loss is going to be one of the main interventions" she said. will prescribe you appetite control Offering the best treatments for fast weight loss. The group page (private) is Weight of the Evidence Group Page Once you ask to join youll be approved.. M with liver cirrhosis had 3 episodes of thrombocytopenia with tablets for 4-5 months for weight loss. Fresh Fruit Cleanse is a weight loss and detox program designed to improve your health through enhanced nutrition. Gastric bypass is surgery that Paleo Diet Recipes For Ulcerative Colitis 2.0 helps you lose weight by changing likely to benefit from weight-loss surgery.. Lose weight and feel great with ...
Ulcerative colitis affects the lining of the colon, but the cause is currently unknown. Learn about ulcerative colitis symptoms and treatment at NorthShore.
Ulcerative Colitis Symptoms, Causes and Treatment explained by Dr. Rajesh Shah at Lifeforce Homeopathy Clinic. Read more about Ulcerative Colitis causes, symptoms and treatment in hindi.
Overview, Symptoms & Causes of Ulcerative Colitis. Resolve Crohns disease ulcerative colitis via natural means. Michelle Honda PhD has great results.
Ulcerative Colitis and INNERzymes,with a diet of coconut products and innerzymes I have my ulcerative colitis under complete control and healing my intestines.
Get the latest information on treatments of ulcerative colitis by using Chinese herbal medicine, diet and medical advances in Ulcerative Colitis, Learn about how lifestyle can affect the disease
Life Science Analytics, Ulcerative Colitis Therapy Area Pipeline Report contains detailed information on the ulcerative colitis drug pipeline. This report
Ulcerative colitis (UC) is a chronic inflammatory condition of the mucosa affecting the rectum and extending up the colon in a continuous manner. Its etiology is unknown, but is most probably the result of the interaction of genetic and environmental factors. Approximately 30% of UC patients will need to undergo surgery at some point during their lifetime, despite progresses made in medical therapies. Indications for surgery include acute severe colitis with its complications, steroid-or antiTNF-refractory colitis (or growth impairment in children), and the onset of colorectal dysplasia/cancer. Recently, the introduction of biologic agents has provided a rationale for prolonging medical therapy before considering surgery in the treatment of active, moderate to severe colitis. When surgery becomes indicated, especially in the urgent setting, it usually involves dealing with immunosuppressive medications, possibly impacting the onset of post-operative septic complications. In both acute and ...
NHS Choices - Crohns Disease. Crohns disease. Ulcerative colitis. Colostomy. Information on Crohns disease from NHS Choices including causes, symptoms, diagnosis, risks and treatment and with links to other useful organisations. Crohns and Colitis UK. Information Line: 0845 130 2233 or 01727 844296. Support Line: 0845 130 3344. crohnsandcolitis.org.uk. Crohns and Colitis UK brings together people of all ages who have Crohns Disease or Ulcerative Colitis, which includes Proctitis, their families and the health professionals involved in their care. They offer support via their information and support lines and 70 country-wide groups.. CICRA (Crohns in Childhood Research Association). cicra.org. Dedicated to creating a wider understanding of Crohns Disease and Ulcerative Colitis particularly as it affects children and young adults. They provide support for sufferers and their families and raise funds to support approved medical research aimed at finding more effective treatments and an ...
A 32-year-old Japanese woman with a 14-month history of ulcerative colitis (UC), pancolitis type, was referred to our institution, because of abdominal distention. Plain abdominal X-ray and computed t
Ulcerative Colitis (UC) is an inflammatory bowel disease that diffusely affects the mucosa of the colon at variable distance from the anal verge. The aetiology of UC is not fully understood, although it is considered to be multifactorial with genetic and environmental factors leading to an inappropriate immunologic response [1,2]. Cytokine imbalance and the production of inflammatory mediators by activated CD4+ T cells are thought to play an important role in the pathogenesis of UC. T-helper type 2 cells and their cytokines are suggested to enhance the development of UC [1].. The primary treatment of UC is medical, first with 5-aminosalicyclic acids (5-ASA) and/or corticosteroids. More refractory patients need immunosuppression with thiopurines, calcineurin inhibitors or TNF alpha blockers. In disease refractory to medical treatment, a (staged) proctocolectomy with ileo-anal pouch anastomosis is usually performed. Approximately 30% of UC patients eventually require surgery [3-6].. A significant ...
Crohns disease and ulcerative colitis are two types of inflammatory bowel disease. Crohns disease usually affects the small intestine, however it can affect any part of the digestive tract and may be segmental. Ulcerative colitis causes inflammatory changes and ulcerations in the colon and rectum. Signs and symptoms of Crohns disease and ulcerative colitis can be similar and diagnosis may be difficult ...
Hi and welcome to Healingwell. I could never understand medicalnese so Im not sure what you biopsy report means. There are different types of colitis but only one Ulcerative Colitis. If it is colitis, then yes there is a chance that it can clear up over time but if its UC then no there is no cure - only medication/supplements to help keep the inflammation under control. So when you go in to see your consultant, you need to ask specifically what your report means in regards to if its colitis or UC. But if its any consolation, no dysplasia is a good thing! That means no cancerous cells were seen. Is the Asacol helping your symptoms ...
Contrast-enhanced ultrasonography (CEUS) is a useful technique to monitor patients with chronic inflammatory bowel disease (IBD) during and after treatment. ...
OK I GUESS I SHOULD START FROM THE BEGINING. IT ALL STARTED BACK IN OCT 3 2007. I WAS FEELING BAD I GUESS STARTING ON OCT 1 2007 WITH HIGH FEVER (101.5 - 102.5) DD AND VOMITING AND STOMACH PAIN. I WENT TO ER ON OCTOBER 3 AND THEY DID A DIRECT ADMIT THOUGHT IT WAS MY GALLBLADDER. SO THEY DID CAT SCAN BLOOD WORK ETC. THE CAT SCAN CAME BACK AND SAID IT WAS PANCOLITIS. MY DOC SCHEDUDLE ME FOR A FLEX SIG THE NEXT DAY AND BIPOSIES. HE TOLD ME IT WAS INFLAMMATION BUT DIDNT THINK IT WAS PANCOLITIS. SO I HAD IV THERAPY ANITBODICS AND PAIN MEDS. I WAS DISCHARGED FROM THE HOSPITAL ON OCT 6, 2007. AND WAS TOLD TO TAKE ASACOL 400 MG 3 TIMES A DAY. MY DOC SAID HE WANTED TO DO A FULL COLONSCOPY ON NOV 22, 2007. NO PROBLEMS SINCE THEN. SO I WENT TO DO MY COLOSCOPY ON NOV 22, 2007 AND HE DID BIOPSIES AS WELL. HE THEN TOLD ME I HAD MILD INFLAMMTION AND THAT HE THOUGHT EVERYTHING WAS OK AND IT WAS ACUTE DIEASE. SO I CONTIUED TO TAKE MY ASACOL AS HE PRESCRIBED AND HE TOLD ME I COULD TAPER DOWN TO TWO A DAY AND THEN ...
Dr. Deepak, GI Surgeon in Chennai, India assesses the severity of ulcerative colitis between mild, moderate and severe before opting for either pharmacological or surgical therapy.
Objectives: Clinical trials have demonstrated the efficacy of vedolizumab in inflammatory bowel disease (IBD). However, these findings may not reflect the clinical practice. Therefore, we aimed to describe a vedolizumab-treated patient population and assess long-term effectiveness.. Materials and methods: Patients initiating vedolizumab between 1 June 2014 and 30 May 2015 were identified through the Swedish National Quality Registry for IBD. Prospectively collected data on treatment and disease activity were extracted. Clinical remission was defined as Patient Harvey Bradshaw index,5 in Crohns disease (CD) and Patient Simple Clinical Colitis Activity index,3 in ulcerative colitis (UC).. Results: Two-hundred forty-six patients (147CD, 92 UC and 7 IBD-Unclassified) were included. On study entry, 86% had failed TNF-antagonist and 48% of the CD patients had undergone1 surgical resection. After a median follow-up of 17 (IQR: 14-20) months, 142 (58%) patients remained on vedolizumab. In total, 54% of ...
All the 5-Asa drugs (Canasa, Apriso, Lialda, Pentasa, Asacol, and Rowasa) treat only the surface of the intestine, and are not approved as monotherapy for crohns since the inflammation extends through all layers of the intestine. They are used alone for ulcerative colitis since the inflammation is present only on the surface. Budesonide is a more effective treatment, especially since your disease is located in the ileum. The other medications your GI could prescribe are immunomodulators like mercaptopurine, azathioprine, and methotrexate which have excellent safety profiles in crohns. Would your insurance approve Pentasa with a prior authorization? Youve tried Lialda and it didnt work, so the next step is usually another drug of the same type. My old insurance used to do this with PPIs, but I had already been through most of them so it was fairly easy to get the next type approved ...
Ulcerative colitis (UC) is a type of inflammatory bowel disease (IBD), along with Crohn disease (CD). Unlike Crohn disease, which can affect any part of the gastrointestinal tract, ulce... more
Background and Aims The polyunsaturated fatty acids (PUFA) arachidonic acid (AA, n-6) and eicosapentaenoic acid (EPA, n-3) are precursors of eicosanoids and other lipid mediators which have critical roles in inflammation. The mediators formed from the different PUFA have different potencies. We hypothesised that metabolic changes associated with colonic mucosal inflammation would modify the bioavailability of the eicosanoid precursors AA and EPA. Methods Colonic mucosa biopsies were obtained from patients with ulcerative colitis and from matched controls. Inflammation was graded endoscopically and histologically. Esterified and non-esterified fatty acids were determined within the biopsies using gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry, respectively. Results Biopsy samples were collected from 69 UC patients (54 providing both inflamed and non-inflamed mucosa) and 69 controls. Inflamed mucosa had higher AA (p , 0.001) and lower EPA (p , 0.010) contents and ...
This featureless smooth appearance of the diseased segment of the large bowel is referred to as lead-pipe sign and is often seen in patients with chronic ulcerative colitis. The patient had a past medical history of long-standing ulcerative colit...
What is it like to live with chronic bowel problems from childhood? One woman reveals her struggles and how she found relief from chronic ulcerative colitis...
Six-year-old Sean Scott adores frogs, mother nature and scientific research.. Getting what he is calling a special tummy is not going to stop him from being outside whenever possible.. Exactly what it entails, nevertheless, is the fact that just about every eight weeks, Sean, accompanied by his dad, Matt, or his mom, Jessie, will have to spend five hours going through an infusion to help remedy the intestinal tract illness that triggers his "special tummy.". Three year ago, Sean, who lives in Yankton, was clinically determined to have Crohns disease, an agonizing, scientifically not curable disease that strikes the digestive tract.. Crohns and ulcerative colitis are regarded with each other as inflamation related digestive tract diseases. Crohns disease can strike just about anywhere across the digestive system, although ulcerative colitis inflames only the large intestine.. One in 200 individuals in the United States are already clinically determined to have Crohns or Ulcerative Colitis, ...
TY - JOUR. T1 - Metachronous occurrence of collagenous colitis and ulcerative colitis. AU - Giardiello, Francis M. AU - Jackson, F. W.. AU - Lazenby, A. J.. PY - 1991. Y1 - 1991. N2 - Collagenous colitis and ulcerative colitis are distinct disorders. A 67 year old woman with clinical and histological evidence of collagenous colitis had an abrupt symptomatic exacerbation while taking anti-inflammatory treatment with sulphasalazine and prednisone. Repeat colorectal endoscopy showed active mucosal inflammation and colonic biopsy specimens were consistent with active ulcerative colitis. After bowel rest, total parenteral nutrition, intensification of the anti-inflammatory regimen, and withdrawal of non-steroidal anti-inflammatory drugs (which she had taken continuously for osteoarthritis) diarrhoea abated. Colorectal biopsy specimens obtained when the patients symptoms had improved showed inactive ulcerative colitis with no evidence of collagenous colitis. This may be the first case to be reported ...
AIMS--To study the effect of proctocolectomy on the antineutrophil cytoplasmic antibody (ANCA) titres in association with ulcerative colitis. METHODS--Serum samples were taken from 15 patients with ulcerative colitis immediately before and at a mean of 24 months after proctocolectomy. Indirect immunofluorescence for ANCA and enzyme immunoassays for myeloperoxidase and proteinase-3 antibodies were employed. A liver biopsy was taken from every patient during the proctocolectomy, and serum liver enzyme activities were also determined. RESULTS--Before proctocolectomy, 13 of the 15 patients had perinuclear antineutrophil cytoplasmic antibodies (p-ANCA). Additionally, one patient had a low tire of classical cytoplasmic ANCA and one had granulocyte specific antinuclear antibodies. After proctocolectomy, the ANCA titres decreased in 10 patients, in two of whom they became negative. The titres remained the same in four patients with positive ANCA and increased twofold in one patient. Only one patient was ...
TY - JOUR. T1 - Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype. T2 - Results of a 25-year follow-up study. AU - Lakatos, Laszlo. AU - Pandur, Tunde. AU - David, Gyula. AU - Balogh, Zsuzsanna. AU - Kuronya, Pal. AU - Tollas, Arpad. AU - Lakatos, Peter Laszlo. PY - 2003/10. Y1 - 2003/10. N2 - Aim: IBD is a systemic disease associated with a large number of extraintestinal manifestations (EIMs). Our aim was to determine the prevalence of EIMs in a large IBD cohort in Veszprem Province in a 25-year follow-up study. Methods: Eight hundred and seventy-three IBD patients were enrolled (ulcerative colitis/UC/: 619, m/f: 317/302, mean age at presentation: 38.3 years, average disease duration: 11.2 years; Crohns disease/CD/: 254, m/f: 125/129, mean age at presentation: 32.5 years, average disease duration: 9.2 years). Intestinal, extraintestinal signs and laboratory tests were monitored regularly. Any alteration ...
There is no quality evidence of the benefit of defunctioning ileostomy (DI) in ileal pouch-anal anastomoses (IPAAs) performed for inflammatory bowel disease (IBD), but most surgical teams currently resort to DI. In the case of a staged procedure with subtotal colectomy first, completion proctectomy with IPAA is performed for healthy patients, namely, after nutritional support, inflammation reduction and immunosuppressive agent weaning. Therefore, the aim of this trial is to assess the need for systematic DI after completion proctectomy and IPAA for IBD. This is a multicenter randomized open trial comparing completion proctectomy and IPAA without (experimental) or with (control) DI in patients presenting with ulcerative colitis or indeterminate colitis. Crohns disease patients will not be included. The design is a superiority trial. The main objective is to compare the 6-month global postoperative morbidity, encompassing both surgical and medical complications, between the two groups. The morbidity of
We have recently shown that QoL, assessed by the Gastrointestinal Quality of Life Index is considerably reduced in collagenous colitis.[22] Although it can be assumed that lymphocytic colitis may also have an effect on the patients QoL, it has not been formally investigated so far. When we started our present trial, we decided to use the generic SF-36,[23] because we were interested to investigate the effect of lymphocytic colitis on the general QoL. Our findings suggest that lymphocytic colitis may affect on general QoL similar to other chronic gastrointestinal diseases.[23] However, only the physical sum score of the SF-36 improved after 6 weeks of treatment with budesonide, whereas the mental sum score did not. A possible reason for this observation might be that the SF-36 is not disease specific and, therefore, not sensitive enough to detect treatment effects. Meanwhile, we have shown that the SF-36 is comparable to the short inflammatory bowel disease questionnaire (SIBDQ) to detect ...
PURPOSE: Disconnection of an ileal pouch-anal anastomosis with repeat ileal pouch-anal anastomosis has been proposed for treatment of ileal pouch-anal anastomosis failure caused by septic or functional complications. We report our experience with repeat ileal pouch-anal anastomosis, and document functional outcome and quality of life.. METHODS: Of 101 patients undergoing laparotomy, ileoanal disconnection, and repeat ileal pouch-anal anastomosis, 80 were referred from other institutions. Indications included: chronic anastomotic leak (n=27), perineal or pouch-vaginal fistula (n=47), anastomotic stricture (n=22), dysfunction/long efferent limb of S-pouch (n=36), and previous ileal pouch-anal anastomosis excision or exclusion (n=6). In 64 cases a "septic" indication was observed. Pathologic features of Crohns disease were present in 4 patients preoperatively and 15 more after repeat ileal pouch-anal anastomosis. Four patients had clinical features of Crohns disease.. RESULTS: Three patients had ...
PURPOSE: Pathophysiology of pouchitis after ileal pouch-anal anastomosis is controversial because of the potential for development of carcinoma. Cyclooxygenase-2-derived prostaglandins may be involved in the inflammatory process and play a role in the pathogenesis of colon cancer. Vascular endothelial growth factor plays a major role in neoangiogenesis and is overexpressed in a number of gastrointestinal malignancies. The goal of this study was to evaluate the expression of cyclooxygenase-2 and vascular endothelial growth factor and to assess neoangiogenesis and epithelial cell proliferation in patients with ileal pouch-anal anastomosis. METHODS: Endoscopic biopsies were obtained from 15 patients with ileal pouch-anal anastomosis without pouchitis (10 biopsies from the ileal pouch and 10 from ileal nonpouch mucosa) and from 15 subjects with irritable bowel syndrome (10 biopsies from normal-appearing ileum and rectum). Cyclooxygenase-1, cyclooxygenase-2, and vascular endothelial growth factor ...
Helpful information on ulcerative colitis, irritable bowel syndrome, and Crohns disease. Nutritional and herbal therapies are given, not only for treating these disorders themselves, but also their complications including diarrhea, constipation, gastrointestinal upset, and special concerns of these diseases in children. Research studies and the actions of different herbs are also mentioned. Herbs discussed include: bayberry, comfrey, plantain, wild yam, cramp bark, chamomile, peppermint, slippery elm, scullcap, marshmallow, psyllium, flaxseed, yellow dock, dandelion, cascara sagrada, senna, buckthorn, linseed, valerian, echinacea, goldenseal, poke root, and kelp.. ...
Chronic or recurrent diarrhea is common in immune-deficient persons, especially those with adult-onset or variable immunodeficiency syndrome (1-3). Chronic inflammatory lesions of the rectum, colon, or small intestine, sometimes treated with sulfasalazine or corticosteroids, have been reported in this population (1, 4-7). Campylobacter jejuni now is recognized as a common cause of diarrhea (8) and sometimes of colitis or ileitis resembling the chronic inflammatory bowel diseases (9, 10). We report the cases of two immune-deficient patients, one with chronic proctitis, who had campylobacter infections.. Patient 1: A 63-year old man had gastric achlorhydria, mild steatorrhea, and hypogammaglobulinemia (serum IgG, 119 ...

Metachronous occurrence of collagenous colitis and ulcerative colitis<...Metachronous occurrence of collagenous colitis and ulcerative colitis<...

"Metachronous occurrence of collagenous colitis and ulcerative colitis",. abstract = "Collagenous colitis and ulcerative colitis ... Collagenous colitis and ulcerative colitis are distinct disorders. A 67 year old woman with clinical and histological evidence ... N2 - Collagenous colitis and ulcerative colitis are distinct disorders. A 67 year old woman with clinical and histological ... AB - Collagenous colitis and ulcerative colitis are distinct disorders. A 67 year old woman with clinical and histological ...
more infohttps://jhu.pure.elsevier.com/en/publications/metachronous-occurrence-of-collagenous-colitis-and-ulcerative-col-5

1992 - Oral mesalamine for ulcerative colitis | 1992 Jan-Feb : Volume 116, Number 1, Page 13 | ACP Journal Club Archives1992 - Oral mesalamine for ulcerative colitis | 1992 Jan-Feb : Volume 116, Number 1, Page 13 | ACP Journal Club Archives

Oral mesalamine for ulcerative colitis. ACP J Club. 1992 Jan-Feb;116:13. doi:10.7326/ACPJC-1992-116-1-013 ... Sulfasalazine remains a first-line drug for the treatment of ulcerative colitis. It is well tolerated by most patients and is ... To evaluate the efficacy and safety of 2 dosage levels of oral mesalamine for treating mild-to-moderate ulcerative colitis. ... Sulfasalazine is an effective treatment for ulcerative colitis, but up to one third of patients will develop side effects, some ...
more infohttp://www.acpjc.org/Content/116/1/issue/ACPJC-1992-116-1-013.htm

Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin<...Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin<...

... coexisting ulcerative colitis have a more benign course of colitis resulting both from improvement of moderately active colitis ... coexisting ulcerative colitis have a more benign course of colitis resulting both from improvement of moderately active colitis ... coexisting ulcerative colitis have a more benign course of colitis resulting both from improvement of moderately active colitis ... coexisting ulcerative colitis have a more benign course of colitis resulting both from improvement of moderately active colitis ...
more infohttps://mayoclinic.pure.elsevier.com/en/publications/ulcerative-colitis-disease-activity-following-treatment-of-associ

Mucosal cell proliferation of the rectal stump in ulcerative colitis patients after ileorectal anastomosis. | IRIS Università...Mucosal cell proliferation of the rectal stump in ulcerative colitis patients after ileorectal anastomosis. | IRIS Università...

... activity and polyamine levels of the rectal epithelium in unoperated ulcerative colitis patients and in ulcerative colitis ... activity and polyamine levels of the rectal epithelium in unoperated ulcerative colitis patients and in ulcerative colitis ... In ulcerative colitis patients the labeling index was significantly increased, and labeled cells were shifted toward the upper ... In ulcerative colitis patients the labeling index was significantly increased, and labeled cells were shifted toward the upper ...
more infohttps://flore.unifi.it/handle/2158/329119

DSpace at EWHA: The prevalence and efficacy of ganciclovir on steroid-refractory ulcerative colitis with cytomegalovirus...DSpace at EWHA: The prevalence and efficacy of ganciclovir on steroid-refractory ulcerative colitis with cytomegalovirus...

... with moderate-to-severe active ulcerative colitis. In patients with steroid-refractory ulcerative colitis, the cytomegalovirus ... especially steroid-refractory ulcerative colitis. Ganciclovir was effective in patients with steroid-refractory ulcerative ... Study: A prospective, multicenter study was conducted in 72 patients with moderate-to-severe ulcerative colitis who were ... The prevalence and efficacy of ganciclovir on steroid-refractory ulcerative colitis with cytomegalovirus infection:a ...
more infohttp://dspace.ewha.ac.kr/handle/2015.oak/222187

Toxic MegacolonToxic Megacolon

Ulcerative colitis. This is a type of inflammatory bowel disease (IBD). It often affects the colon and rectum. ... HIV infection or AIDS. For people with HIV, cytomegalovirus (CMV) colitis is the leading cause of toxic megacolon ...
more infohttp://healthlibrary.lomalindahealth.org/Library/DiseasesConditions/Adult/Digestive/134,180

Small duct autoimmune sclerosing cholangitis and Crohn colitis in a 10-year-old child. A case report and review of the...Small duct autoimmune sclerosing cholangitis and Crohn colitis in a 10-year-old child. A case report and review of the...

... typically ulcerative colitis (UC) while fewer cases of indeterminate colitis (IC) and Crohn disease (CD) has been described [5 ... predominantly ulcerative colitis. We report a unique case of a 10-year-old Danish boy with severe small duct autoimmune ... 22], who described a 13-year-old boy with concomitant Crohn colitis and AISC with GEL, who showed long-term remission of liver ... This report describes a rare case of AISC with concomitant Crohn colitis in a child with a unique hyperplastic and destructive ...
more infohttps://diagnosticpathology.biomedcentral.com/articles/10.1186/1746-1596-7-100

Ulcerative colitis - NHS ChoicesUlcerative colitis - NHS Choices

Find out about ulcerative colitis, a long-term (chronic) condition where the colon and rectum (large intestine or large bowel) ... Symptoms of ulcerative colitis. The main symptoms of ulcerative colitis are:. *recurring diarrhoea, which may contain blood, ... What causes ulcerative colitis?. Ulcerative colitis is thought to be an autoimmune condition. This means the immune system - ... How ulcerative colitis is treated. Treatment for ulcerative colitis aims to relieve symptoms during a flare-up and prevent ...
more infohttp://www.nhs.uk/Conditions/ulcerative-colitis/Pages/Introduction.aspx

Ulcerative ColitisUlcerative Colitis

... is a lifelong condition.. Ulcerative colitis may begin with a breakdown in the lining of the intestine. The ... Ulcerative colitis substantially increases the risk of colon cancer.. Symptoms. The symptoms of ulcerative colitis vary. Some ... Ulcerative colitis is a lifelong condition, unless the large intestine is surgically removed. Most people with ulcerative ... If you have ulcerative colitis, you can decrease the toll it takes on your body. To do this, eat a well-balanced, nutritious ...
more infohttps://www.womenshealthmag.com/health/a19950816/ulcerative-colitis/

Ulcerative ColitisUlcerative Colitis

Fulminant colitis is a possibility, which may require colectomy. ... Ulcerative colitis is characterized by bouts of diarrhea, ... Ulcerative colitis is a chronic inflammation of the large intestines. Symptoms of ulcerative colitis are repeated attacks of ... Like other diseases of immune origin, there is no cure for ulcerative colitis.. The severity of ulcerative colitis symptoms ... Crohn s disease and ulcerative colitis differ in that ulcerative colitis almost always involves only the large bowel whereas ...
more infohttps://www.medindia.net/patients/patientinfo/Ulcerative-Colitis.htm

Ulcerative colitis | The BMJUlcerative colitis | The BMJ

What is ulcerative colitis and who gets it?. Ulcerative colitis is an idiopathic inflammatory bowel disease (IBD), which ... Ulcerative colitis is an inflammatory disorder of the gastrointestinal tract that affects the colorectum. It often presents in ... "ulcerative colitis". We limited studies to those conducted in adults and focused on systematic reviews, meta-analyses, and high ... Ulcerative colitis. BMJ 2013; 346 doi: https://doi.org/10.1136/bmj.f432 (Published 05 February 2013) Cite this as: BMJ 2013;346 ...
more infohttp://www.bmj.com/content/346/bmj.f432.full

Ulcerative Colitis | HealthCentralUlcerative Colitis | HealthCentral

quiz How Much Do You Know About Ulcerative Colitis? article First in the Family with a Genetic Disease: What Its Like article ... Crohns and Ulcerative Colitis: Accepting Your Condition We are taught at a very young age not to discuss what happens behind ... and even though Crohns disease and ulcerative colitis go far beyond the bathroom, patients often stay quiet about their ...
more infohttps://www.healthcentral.com/ulcerative-colitis?ic=also

Management of ulcerative colitis - WikipediaManagement of ulcerative colitis - Wikipedia

... by the type of ulcerative colitis. Aminosalicylates are the main anti-inflammatory drugs used to treat ulcerative colitis. ... Ulcerative colitis is a form of colitis, a disease of the intestine, specifically the large intestine or colon, that includes ... Ulcerative colitis is a disease that affects many parts of the body outside the intestinal tract. In rare cases the extra- ... Ulcerative Colitis Practice Guidelines in Adults, Am. Coll. Gastroenterology, 2004. PDF Jowett, S L; Seal, C J; Pearce, M S; ...
more infohttps://en.wikipedia.org/wiki/Management_of_ulcerative_colitis

Ulcerative colitis | pathology | Britannica.comUlcerative colitis | pathology | Britannica.com

The most common symptoms of ulcerative colitis are bloody diarrhea and abdominal pain. Other symptoms include fatigue, weight ... Ulcerative colitis, inflammation of the large intestine (colon), especially of its mucous membranes, characterized by patches ... colon) in the Western world, ulcerative colitis, is idiopathic (i.e., of unknown cause). Ulcerative colitis varies from a mild ... More About Ulcerative colitis. 6 references found in Britannica articles. Assorted References. *major reference* In ...
more infohttps://www.britannica.com/science/ulcerative-colitis

Infliximab and Ulcerative ColitisInfliximab and Ulcerative Colitis

Ulcerative colitis (UC) is one of the main forms of inflammatory bowel disease. The condition causes the colon and rectum to ... Ulcerative colitis (UC) is one of the main forms of inflammatory bowel disease. The condition causes the colon and rectum to ... www.bupa.co.uk/health-information/directory/u/ulcerative-colitis. *www.crohnsandcolitis.org.uk/.../Ulcerative-Colitis.pdf ...
more infohttps://www.news-medical.net/health/Infliximab-and-Ulcerative-Colitis.aspx

Ulcerative colitis: Medications and treatmentsUlcerative colitis: Medications and treatments

Ulcerative colitis medications include corticosteroids and immunomodulators. Other medical and natural treatments, such as ... Risks of leaving ulcerative colitis untreated Ulcerative colitis is an inflammatory bowel disease that can vary in severity. If ... Ulcerative colitis stool: A visual guide. Ulcerative colitis may cause differences in the appearance of a persons stool. Learn ... Ulcerative colitis remission: What to know People with ulcerative colitis may experience flare-ups, times when symptoms are ...
more infohttps://www.medicalnewstoday.com/articles/324832.php

Ulcerative ColitisUlcerative Colitis

... Online Medical Reference - from diagnosis through treatment. Authored by Bret A. Lashner of the Cleveland ... Management of ulcerative colitis is described in practice guidelines published in 2010.4 The severity of the ulcerative colitis ... Ulcerative colitis is a systemic disease; there are many extraintestinal manifestations. Approximately 2% of ulcerative colitis ... The differential diagnosis ulcerative colitis includes infectious colitis, antibiotic-associated colitis, and solitary rectal ...
more infohttp://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/gastroenterology/ulcerative-colitis/

Ulcerative ColitisUlcerative Colitis

... is a type of inflammatory bowel disease (IBD) that happens only in the colon. It causes the inner lining of ... Who Gets Ulcerative Colitis?. Ulcerative colitis tends to run in families. But not everyone with ulcerative colitis has a ... What Is Ulcerative Colitis?. Ulcerative colitis is a condition that causes the inner lining of the large intestine (colon) to ... What Causes Ulcerative Colitis?. The exact cause of ulcerative colitis is not clear. It is probably a combination of genetics, ...
more infohttp://teenshealth.org/en/teens/ulcerative-colitis.html

Ulcerative Colitis - Multiple Languages: MedlinePlusUlcerative Colitis - Multiple Languages: MedlinePlus

Health Information on Ulcerative Colitis: MedlinePlus Multiple Languages Collection ... Ulcerative Colitis: MedlinePlus Health Topic - English Colitis ulcerativa: Tema de salud de MedlinePlus - español (Spanish) ... Ulcerative Colitis - 繁體中文 (Chinese, Traditional (Cantonese dialect)) Bilingual PDF ...
more infohttps://medlineplus.gov/languages/ulcerativecolitis.html

Ulcerative colitis: MedlinePlus Medical EncyclopediaUlcerative colitis: MedlinePlus Medical Encyclopedia

Ulcerative colitis is a condition in which the lining of the large intestine (colon) and rectum become inflamed. It is a form ... Inflammatory bowel disease - ulcerative colitis; IBD - ulcerative colitis; Colitis; Proctitis; Ulcerative proctitis ... Ulcerative colitis is a condition in which the lining of the large intestine (colon) and rectum become inflamed. It is a form ... Ulcerative colitis may affect any age group. There are peaks at ages 15 to 30 and then again at ages 50 to 70. ...
more infohttps://medlineplus.gov/ency/article/000250.htm

Ulcerative Colitis News » TopixUlcerative Colitis News » Topix

News for Ulcerative Colitis continually updated from thousands of sources on the web : New strategies to improve the quality of ... Topix › Ulcerative Colitis News Ulcerative Colitis News. News on Ulcerative Colitis continually updated from thousands of ...
more infohttp://www.topix.com/health/ulcerative-colitis

Ulcerative Colitis - Colitis - MedHelpUlcerative Colitis - Colitis - MedHelp

I was diagnosed with ulcerative colitis in early stage. Right now I am talking Lialda 1.2 mg 3 tablets once a day. The above ... Ulcerative Colitis. Hi, A month ago I had blood in my stools and sever abdominal cramps. I was diagnosed with ulcerative ... I was diagnosed with ulcerative colitis in early stage. Right now I am talking Lialda 1.2 mg 3 tablets once a day. The above ... I found that with ulcerative colitis that low fiber and no dairy worked best for me. I have a blog about U.C. http://www. ...
more infohttp://www.medhelp.org/posts/Colitis/Ulcerative-Colitis/show/1758912

What is ulcerative colitis (UC)?What is ulcerative colitis (UC)?

Ulcerative colitis (UC) is a type of inflammatory bowel disease (IBD), along with Crohn disease (CD). Unlike Crohn disease, ... The severity of ulcerative colitis can be graded as follows:. * Mild - Bleeding per rectum and fewer than 4 bowel motions per ... What is ulcerative colitis (UC)?. Updated: Apr 23, 2019 * Author: Ali Nawaz Khan, MBBS, FRCS, FRCP, FRCR; Chief Editor: Eugene ... Ulcerative colitis (UC) is a type of inflammatory bowel disease (IBD), along with Crohn disease (CD). Unlike Crohn disease, ...
more infohttps://www.medscape.com/answers/375166-181647/183084-overview

cabbage - Ulcerative Colitiscabbage - Ulcerative Colitis

I didnt used to have problem with cabbage but since my colectomy I tried eating cole slaw and it gave me D early the next ... diagnosed with colitis 2007. malrotated colon. no cecal valve, removed during surgery. gastritis. VSL #3. Amitriptyline to slow ...
more infohttps://www.healingwell.com/community/default.aspx?f=38&m=960001
  • A 67 year old woman with clinical and histological evidence of collagenous colitis had an abrupt symptomatic exacerbation while taking anti-inflammatory treatment with sulphasalazine and prednisone. (elsevier.com)
  • Mucosal protection by phosphatidylcholine as new therapeutic concept in ulcerative colitis]. (medindia.net)
  • Single-contrast enema study in a patient with total colitis shows mucosal ulcers with a variety of shapes, including collar-button ulcers, in which undermining of the ulcers occurs, and double-tracking ulcers, in which the ulcers are longitudinally orientated. (medscape.com)
  • Postevacuation image obtained after a single-contrast barium enema study shows extensive mucosal ulceration resulting from Shigella colitis. (medscape.com)
  • Patients with fulminant or toxic colitis, or toxic megacolon often have more than 10 bowel movements in a day, continuous bleeding, abdominal distention and tenderness, and radiologic evidence of edema and, in some cases, bowel dilation. (clevelandclinicmeded.com)
  • There are host of digestive ailments which benefit enormously from a gluten free Paleo diet: IBS, Crohns, Celiac, diverticulitis…and ulcerative colitis . (robbwolf.com)
  • If you've been diagnosed with ulcerative colitis and think you may be having a severe flare-up, contact your GP or care team for advice. (www.nhs.uk)